WO2011106276A1 - Task channel antagonists - Google Patents

Task channel antagonists Download PDF

Info

Publication number
WO2011106276A1
WO2011106276A1 PCT/US2011/025596 US2011025596W WO2011106276A1 WO 2011106276 A1 WO2011106276 A1 WO 2011106276A1 US 2011025596 W US2011025596 W US 2011025596W WO 2011106276 A1 WO2011106276 A1 WO 2011106276A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
6alkyl
10aryl
mmol
compound
Prior art date
Application number
PCT/US2011/025596
Other languages
French (fr)
Inventor
Craig Coburn
Jiabing Wang
Vince Santarelli
Shuangxi Hu
Mingxiang Cui
Bin Hu
Jingchao Dong
Yunfu Luo
Richard M. Soll
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/070751 external-priority patent/WO2011103715A1/en
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of WO2011106276A1 publication Critical patent/WO2011106276A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Definitions

  • the invention relates generally to compounds which act as modulators, e.g., antagonists of TASK channels, particularly, TASK-1 and/or TASK-3, compositions and therapeutic uses thereof.
  • Potassium channels are membrane proteins that play an important role in many physiological processes. There are three major families of potassium channel proteins each with structural and functional distinctions characterized by the number of transmembrane domams (2, 4 or 6). The first and second families of potassium channels are the voltage-dependent potassium channels (K v ) and the inwardly rectifying potassium channel (3 ⁇ 4). The members of the third family are known as the KCNK, or 3 ⁇ 4p (Coetzee W. J. et al; New York Acad Sci, 1999 (868),
  • the TASK channels are generally referred to as TASK-1 (which is also known as (aka) KCNK3 or K 2P 3J), TASK-2 (aka KCNK5 or K 2 P5.1), TASK-3 (aka KCNK9 or K 2P 9.1), TASK-4 (aka KCNK17 or K 2P 17.1 or TALK-2) and TASK-5 (aka KCNK 15 or K 2P 15.1).
  • TASK-1 and TASK- 3 channels have the greatest homology within this family with a greater than 0% amino acid identity. For background discussion see Goldstein, S.A.N., et al, Nat. Rev. Neurosci.
  • the TASK channels are sensitive to extracellular pH within physiological range displaying inhibition at acidic pH and activated at alkaline pH (Duprat F., et al., EMBO J. 1997 (16), 5464-5471).
  • TASK-1 is expressed in the brain, spinal ganglia, peripheral tissues such as pancreas, placenta, uterus, lung, heart, kidney, small intestine and stomach, and have been detected in motor neurons of the locus coeruleus and hypoglossal nerve (a motor cranial nerve which is integrally involved in the maintenance of the upper respiratory pathways).
  • TASK-3 channels are primarily expressed in the cerebellum (Medhurst, A.D., et al., Mol Brain Res. 2001 (86), 101-114).
  • TASK-1 channels have been shown to be involved in respiratory regulation in respiratory neurons of the brainstem, in carotid bodies and motor neurons of the hypoglossal nerve, and also in neuroepithelial cells of the lung.
  • the lowering of the pH and resultant blockage of the pH-dependent TASK-1 channels that occur from inadequate respiration (e.g., hypoxia, hindered breathing, excessive physical stress) leads to depolarization of the cells, which leads to the activation of the neurons involved in the respiratory regulation [Buckler K.J., et al., J. Physiol. 2000 (525), 135-142; Bayliss, D.A., et al., Respiration Physiology 2001 (129), 159-174).
  • Blocking TASK channels by increasing the activity of chemosensitive neurons in conjuction with activation of the motor neurons of the hypoglossal nerve, can stimulate respiration, stabilize the upper respiratory pathways and protect the pathways from collapse and occlusion.
  • Stabilization of the upper respiratory pathways can also help eliminate or inhibit snoring.
  • blocking TASK-1 channels can be beneficial in the treatment of respiratory disorders such as sleep apnea.
  • TASK-1 channesl have also been found in smooth muscle cells of mesenterial and pulmonary arteries, and are suggested to be involved in acidosis-induced pulmonary
  • TASK-1 channels are responsible for programmed cell death (apoptosis) in granulose cells, and that the ceil death can be preventing by blocking the TASK-3 (Patel A. J., Pflugers Arch, 2004 (448), 261-273).
  • TASK-1 channels are responsible for programmed cell death (apoptosis) in granulose cells, and that the ceil death can be preventing by blocking the TASK-3 (Patel A. J., Pflugers Arch, 2004 (448), 261-273).
  • TASK-1 and/or TASK-3 channels could lead to therapeutic treatment of neurodegenerative disorders.
  • the TASK-3 gene has been found in several human carcinoma tissues (e.g., breast cancer, colon cancer, lung cancer), which leads to the belief that TASK-3 inhibitors may useful as an anticancer drug. See Mu D., et al., Cancer Cell 2003 (3), 297-302; and Pei, L., et al., Proc. Natl. Acad. Sci. USA 2003 (100), 7803-7807.
  • TASK-3 antagonists may also be useful for the treatment of respiratory disorders (e.g., Cheyne-Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia) , sleep disorders, excessive daytime sleepiness, sleep apneas, snoring, neurodegenerative disorders, cognitive impairment (e.g., dementia, Alzheimer's disease) or major depressive disorder, Parkinson's disease, Huntington's disease.
  • respiratory disorders e.g., Cheyne-Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia
  • sleep disorders e.g., excessive daytime sleepiness, sleep apneas, snoring
  • cognitive impairment e.g., dementia, Alzheimer's disease
  • major depressive disorder Parkinson's disease, Huntington's disease.
  • One aspect of the present invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders which have TASK-1 and/or TASK-3 -related damage as a secondary cause.
  • Another aspect of this invention is use of the TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prevention of cancer disorders (e.g., breast cancer, lung cancer, colon cancer, prostate cancer), respiratory disorders (e.g., Cheyne-Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia) , sleep disorders, excessive daytime sleepiness, sleep apneas, snoring, neurodegenerative disorders, cognitive impairment (e.g., dementia, Alzheimer's disease) or major depressive disorder, atypical depression, Parkinson's disease, and Huntington's disease.
  • cancer disorders e.g., breast cancer, lung cancer, colon cancer, prostate cancer
  • respiratory disorders e.g., Cheyne-Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia
  • Rl represents Q-6 alkylC(0)OCi -6alkyl, (CH2) n C6-10aryl, (CH2) n C5-10heterocycle, (CH2) n C3- lOcycloalkyl N(CH3)(CH2)nC(O)NHC6-10aryl, and N(CH3)(CH2) n C5-10heterocycle; said cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of R a ;
  • R represents H, Q-6 a kyl, C(O)(CH2) n C6-10aryl, C(O)O(CH2) n C6-10ary C(0)(CH2) n C5- lOheterocycle, (CH2) n C6-10aryl, SO2C6-IO ary SO2C5-IO heterocycle, C(O)NHC6-10ary
  • Ra represents (CH2) n OH, (CH2) n CN, C(OH)CN, Cl-6 alkyl, CH(OH)(CH2) n C6-10 aryl,
  • R3, R3a s R4 R4a independently represent hydrogen or C ⁇ -ft alkyl; and n represents 0 to 4.
  • This invention also relates to compositions and methods for using the compounds disclosed herein. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
  • the present invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK- 3, such as cancer disorders (e.g., breast cancer, lung cancer, colon cancer, prostate cancer), respiratory disorders (e.g., Cheyne- Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia) , sleep disorders, excessive daytime sleepiness, sleep apneas, snoring, neurodegenerative disorders, cognitive impairment (e.g., dementia, Alzheimer's disease) or major depressive disorder, Parkinson's disease, and Huntington's disease.
  • cancer disorders e.g., breast cancer, lung cancer, colon cancer, prostate cancer
  • respiratory disorders e.g., Cheyne- Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders,
  • n in R and Rl is 0-2, preferably
  • RY 1 is the same as R a ; or when two yl are present they may combined to form a C3-10 cyclic group optionally having 1-2 heteroatoms selected from N, O, and S, said cyclic group optionally substituted with 1 to 3 groups of R a ; and R y2 is H, halo, or OH and all other variables are as described herein.
  • n in Ryl is 0-1, preferably
  • Still another embodiment of the present invention is realized when 1 is and all other variables are as originally described.
  • a subembodiment of this invention is realized when R l is Cl-galls l, C(0)OCi _6alkyl, C(0)Cl_6aIkyl, C3-6c cIoalk l, C(0)C3- gcycloalkyl, C5. 0 heterocycle, said alkyl, heterocyclyl, and cycloalkyi optionally substituted with 1 to
  • R* is and all other variables are as originally described.
  • a subembodiment of this invention is realized when R l is Ci _ ealkyl, C(0)OCi -6alkyl, C(0)Oi _6alkyl, C3-6cycloalkyl , C(0)C3-6cycloalkyl, C5-10 heterocycle, said alkyl, cycloalkyi, heterocycle optionally substituted with 1 to 3 groups of R a .
  • Yet another embodiment of the present invention is realized when 1 is and all other variables are as originally described.
  • a subembodiment of this invention is realized when R is C(0)C1 -6alkyl, C(O)(CH2) n C6-10aryl, C(O)(CH2) n C5-10heterocycle,
  • Still another embodiment of the present invention is realized when Rl is and all other variables are as originally described..
  • R3, R3a ; R4 an ⁇ j j3 ⁇ 44a are all hydrogen and all other variables are as originally described.
  • Still another embodiment of this invention is realized when R is C(O)(CH2)nC6 ⁇ 10 ar yl > C(O)(CH2)nC5-10he erocycle, SO2C6-IO aryl, or SO2C5-10 heterocycle, said aryl and heterocycle optionally substituted with 1 to 3 groups of R a .
  • a subembodiment of this invention is realized when R is C(O)(CH2)nC6-10 ar yl substituted with 1 to 3 groups of R a .
  • Still another embodiment of this invention is realized when R is C(0)phenyl and the R a substitution is an optionally substituted phenyl group, substituted with 1 to 3 groups of R ⁇ .
  • Yet another subembodiment of this invention is realized when R SO2C6-10aryl substituted with 1 to 3 groups of Ra.
  • R is represented by formula ⁇ :
  • R w and R wa are independently selected from the group consisting of H, OC 1 -galkyl, 0(CH2)nC6-l Qsryl, SCl-6alkyl, CF3, OCF3, CN, Cl-6 alkyl, and halo.
  • Rw and R wa are both hydrogen.
  • R is pheny or pyridyl optionally substituted by 1 to 3 groups of R a .
  • a subembodiment of this invention is realized when R is optionally substituted biphenyl.
  • R3a, Ryl RW an( j Rwa is as previously described.
  • a subembodiment of formula III is realized when Ryl is Q-6aIkyl, C(0)OCl_6alkyl, C(0)Cl -6alkyl, C3-6cycloalkyl , C(0)C3- gcycloalkyl, said alkyl and cycloalkyl optionally substituted with 1 to 3 groups of R a .
  • Another subembodiment of formula ⁇ is realized when Ryl is C(0)OCH2CH3, C(0)CH2CH3,
  • variable e.g. aryl, heterocycle, R*, etc.
  • R3 ⁇ 4 is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
  • a nitrogen e.g., nitrogen atom on a pyridyl group
  • sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
  • alkyl encompasses groups having the prefix “alk” such as, for example, alkoxy, alkanoyl, alkenyl, and alkynyl and means carbon chains which may be linear or branched or combinations thereof.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, and heptyl.
  • alkenyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond.
  • alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
  • alkenyl is C2-C6 alkenyl.
  • Preferred alkynyls are C2-C6 alkynyl.
  • alkenyl “alkynyl” and other like terms include carbon chains containing at least one unsaturated C-C bond. In the case of alkenyl it has a double bond and in the case of alkynyl a triple bond is expected.
  • fluoroalkyl refers to an alkyl substituent as described herein containing at least one flurine substituent.
  • cycloalkyl refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms.
  • examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • Q-6 includes alkyls containing 6, 5, 4, 3, 2, or 1 carbon atoms
  • alkoxy as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom.
  • alkoxy also includes alkyl ether groups, where the term 'alkyl' is defined above, and 'ether' means two alkyl groups with an oxygen atom between them.
  • alkoxy groups examples include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as 'dimethyl ether'), and methoxyethane (also referred to as 'ethyl methyl ether').
  • aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, napthyl, tetrahydronapthyl, indanyl, or biphenyl.
  • heterocycle, heterocyclyl, or heterocyclic represents a stable 4- to 7-membered monocyclic or stable 8- to 11-mernbered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocycle or heterocyclic includes heteroaryl moieties.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyi, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl,
  • the heterocyclic group is a heteroaryl group.
  • heteroaryl refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms;
  • heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyl.
  • the heterocyclic group is fused to an aryl or
  • heteroaryl group examples include, without limitation,
  • heteroaryl represents a stable 5- to 7- membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyi, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carbolme, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole,
  • heterocycloalkyls examples include azetidinyl, pyrrolidinyl, piperidinyi, piperazinyl, morpholinyl, tetrahydrofuranyl, imidazolinyl, pyrolidin-2-one, piperidin-2-one, and thiomorpholinyl.
  • heteroatom means O, S or N, selected on an independent basis.
  • a moiety that is substituted is one in which one or more hydrogen atoms have been independently replaced with another chemical substituent.
  • substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl, 3-chIoro-4-fiuoro-phenyl, 2,4-fluoro-3-propylphenyl.
  • substituted n-octyls include 2,4-dimethyl-5-ethyl-octyl and 3- cyclopentyloctyl. Included within this definition are methylenes (-C3 ⁇ 4 ⁇ ) substituted with oxygen to form carbonyl (-CO-).
  • substituted it is meant that the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents.
  • Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular ⁇ CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino,
  • Preferred substituents which are themselves not further substituted (unless expressly stated otherwise) are:
  • Halogen refers to fluorine, chlorine, bromine and iodine.
  • mammal “mammalian” or “mammals” includes humans, as well as animals, such as dogs, cats, horses, pigs and cattle.
  • phrases "effective amount” or “therapeutically effective amount” mean a concentration of TASK- 1 and/or TASK-3 receptor complex modulator sufficient to inhibit or enhance the effect of the TASK-1 and/or TASK-3 receptor complex.
  • Compounds described herein may contain one or more double bonds and may thus give rise to cis/trans isomers as well as other conformational isomers.
  • the present invention includes all such possible isomers as well as mixtures of such isomers unless specifically stated otherwise.
  • the compounds of the present invention may contain one or more asymmetric centers and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I.
  • different isotopic forms of hydrogen (H) include protium (lH) and deuterium (2H), Protium is the predominant hydrogen isotope found in nature.
  • Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically- enriched reagents and/or intermediates.
  • references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations.
  • the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines.
  • Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N- dibenzylethylenediamine, diethylamine, 2-dtethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorphoHne, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamiiie
  • the compound of the present invention When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • compositions of the present invention comprise compounds of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants.
  • additional therapeutic agents can include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists, iv) sodium channel antagonists, v) NMD A receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) N 1 antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID”), ix) selective serotonin reuptake inhibitors ("SSRI”) and/or selective serotonin and norepinephrine reuptake inhibitors (“SSNRI”), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xBi) valproate, xiv) neurontin (gabapent
  • compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the instant compounds have clinical uses for the treatment of epilepsy and partial and generalized tonic seizures. They are also useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and for treating multiple sclerosis.
  • the present compounds are useful for the treatment of tachy-arrhythmias.
  • the instant compounds are useful for the treatment of neuropsychiatric disorders, including mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders, dysthymic disorders and atypical depression, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders.
  • another aspect of this invention is the use of the compounds of formula I in the manufacture of a medicament to treat diseases associated with TASK-1 and/or TASK-3 receptor complex,
  • mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats guinea pigs, or other bovine, ovine, equine, canine, feline, rodent such as mouse, species can be treated.
  • the method can also be practiced in other species, such as avian species (e.g., chickens).
  • a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors
  • SSRIs monoamine oxidase inhibitors
  • MAOIs monoamine oxidase inhibitors
  • RJMAs reversible inhibitors of monoamine oxidase
  • SNRIs serotonin and noradrenaline reuptake inhibitors
  • a-adrenoreceptor antagonists atypical anti-depressants
  • benzodiazepines 5-HTiA agonists or antagonists, especially 5-HTIA partial agonists, neurokinin- 1 receptor antagonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof.
  • compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions and disorders, as well as to prevent other conditions and disorders associated with calcium channel activity.
  • Creams, ointments, jellies, solutions, or suspensions containing the instant compounds can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.
  • Dosage levels from about 0.01 mg/kg to about 140 mg kg of body weight per day are useful in the treatment of neuropsychiatric disorders, or alternatively about 0.5 mg to about 7 g per patient per day.
  • neuropsychiatric disorders may be effectively treated by the administration of from about 0.01 mg to about 75 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day
  • neuropsychiatric disorders may be effectively treated by the administration of from about 0.01 mg to about 125 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 5.5 g per patient per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration to humans may conveniently contain from about 0.5 mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may ary from about 5 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about 1 mg to about 1000 nig of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
  • the specific dose level for any particular patient will depend upon a variety of factors. Such patient-related factors include the age, body weight, general health, sex, and diet of the patient. Other factors include the time and route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
  • the compounds of the invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in- water emulsion or as a water-in-oil liquid emulsion.
  • the compounds of the invention, or pharmaceutically acceptable salts thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy.- In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a
  • compositions in combination with one or more therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, - magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • any of the usual pharmaceutical media can be employed.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used; or in the case of oral solid preparations such as powders, capsules and tablets, carriers such as starches, sugars, microcrystallme cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included.
  • carriers such as starches, sugars, microcrystallme cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included.
  • tablets and capsules represent the most advantageous oral dosage unit form in which solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • controlled release means and/or delivery devices may also be used in administering the instant compounds and compositions.
  • any convenient pharmaceutical media may be employed.
  • water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars,
  • microcrystalline cellulose diluents, granulating agents, lubricants, binders, and disintegrating agents can be used to form oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are advantageous oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet advantageously contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule advantageously containing from about 0.1 mg to about 500 mg of the active ingredient.
  • a tablet, cachet, or capsule conveniently contains 0.1 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of the active ingredient taken one or two tablets, cachets, or capsules, once, twice, or three times daily.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.
  • a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage, and thus should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, and dusting powder.
  • compositions can be in a form suitable for use in transdermal devices.
  • These formulations may be prepared, utilizing a compound represented of the invention, or
  • a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid, such as, for example, where the mixture forms unit dose suppositories.
  • suitable carriers include cocoa butter and other materials commonly used in the art.
  • the suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants).
  • preservatives including anti-oxidants
  • compositions containing a compound of the invention, or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
  • the instant compounds can be utilized in combination with one or more therapeutically active compounds, hi particular, the inventive compounds can be advantageously used in combination with i) opiate agonists or antagonists, ii) other calcium channel antagonists, iii) 5HT receptor agonists or antagonists, including 5-HTJA agonists or antagonists, and 5-HTIA partial agonists, iv) sodium channel antagonists, v) N-metbyl-D- aspartate (NMD A) receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) neurokinin receptor 1 (NK1) antagonists, viii) non-steroidal anti-inflammatory drugs (NSAID), ix) selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii)
  • MS molecular sieves
  • MsCl methanesulfonyl chloride
  • NaH sodium hydride
  • Na2S04 sodium sulfate
  • Pd(OH)2 palladium hydroxide, 20% on carbon
  • PE petroleum ether
  • Ph Ph
  • POCI3 phosphorous oxychloride
  • the present compounds can be prepared according to the procedures provided in the Examples.
  • the following Examples further describe, but do not limit, the scope of the invention.
  • NMR data is in the form of delta ( ⁇ ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent.
  • TMS tetramethylsilane
  • Conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. Broad; etc.
  • “Ar” signifies an aromatic signal.
  • the procedures described herein for synthesizing the compounds may include one or more steps of protecting group manipulations and of purification, such as, re-crystallization, distillation, column chromatography, flash chromatography, thin-layer chromatography (TLC), radial chromatography and high-pressure chromatography (HPLC).
  • the products can be characterized using various techniques well known in the chemical arts, including proton and carbon- 13 nuclear magnetic resonance ( H and C NMR), infrared and ultraviolet spectroscopy (IK and UV), X-ray crystallography, elemental analysis and HPLC and mass spectrometry
  • solvents are those which will at least partially dissolve one or all of the reactants and will not adversely interact with either the reactants or the product.
  • Suitable solvents are aromatic hydrocarbons (e.g, toluene, xylenes), halogenated solvents (e.g, methylene chloride, chloroform, carbontetrachloride, chlorobenzenes), ethers (e.g, diethyl ether,
  • nitriles e.g, acetonitrile, propionitrile
  • ketones e.g, 2-butanone, dithyl ketone, tert-butyl methyl ketone
  • alcohols e.g, methanol, ethanol
  • Suitable bases are, generally, alkali metal hydroxides, alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, and calcium hydroxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides such as lithium amide, sodium amide and potassium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, and cesium hydrogen carbonate; alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and magnesium ethoxide; alkali metal alkyls such as methyllithium, n-butyllithium, sec-butyllithium, t-bultyllithium, phenyllithium, alky
  • compounds of this invention contain one or more stereocenters that may be prepared as single enantiomers or diastereomers, or as mixtures containing two or more enantiomers or diastereomers in any proportion.
  • the compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail.
  • the general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
  • the synthesis of the compounds in this invention can be synthesized using one of the methods described in schemes A or B.
  • Cyclocondensation of an appropriately substituted keto ester 1 using formamidine and a base catalyst such as sodium methoxide can provide bicyclic structure 2 which can subsequently be deprotected using catalytic hydrogenation to afford amine 3.
  • Amine 3 can then be coupled using an appropriately substituted carboxylic acid and an amide coupling agent to give intermediate pyrazinone 4 which can be converted the the corresponding chloropyrimidine 5.
  • the penultimate compounds 5 can then be heated with a cyclic amine in the presence of an acid scavenger to afford the final compounds 6 which could be functional ized further depending on the structure of the target.
  • Scheme B represents an alternative procedure for the synthesis of the claimed compounds and begins with the bicyclic pyrazinone 2 from scheme A above.
  • Chloropyrimidine formation can be effected by the action of an electrophilic halogenating agent such as phosphorous oxychloride to afford intermediate 3.
  • Nucleophilic aromatic substitution with an appropriately substituted cyclic amine can provide intermediate 4 which can then be deprotected using hydrogenating conditions.
  • the resulting amine can then be functionalized using a variety of acylating or sulfonylating agents to provide the desired targets 6.
  • Step D A mixture of compound 3 (50 g, 0.15 mol), phosphoryl chloride (100 mL, 1.0 mol) and acetonitrile (500 mL) and DMF (2 mL) was heated to reflux at 70°C for 5 hour. After cooling, the mixture was evaporated to give the remaining black residue, which was taken up in DCM (600 mL) and poured into 200 mL of ice-water. The mixture was carefully neutralized with the addition of solid NaHC0 3 to pH ⁇ 9. The organic layer was separated and the aqueous layer was washed with DCM twice. The combined organic phase was washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was then purified on silica gel column (MeOH/DCM (0-5%)) to yield the title compound 4 as a brown solid (31 g). MS (ESEI): 35 .0 [M+lf
  • Example 7 cycIopropyI(l- ⁇ 6-[(4'-fluorobiphenyI-4-yl)carbonyl]-5,6,7,8- tetra- hydropyrido[4,3- d]pyrimidin ⁇ 4-yl ⁇ piperidm-4-yl)methanone
  • Example 8 l- ⁇ l-J6-(biphenyI-4-yIcarbonyl)-5,6,7,8- tetrahydropyrido[4,3-d]- pyrimidin-4- yl]piperidin-4-yl ⁇ propan-l-one
  • Example 9 l- ⁇ l-[6-(biplienyl-4 ⁇ ylcarbonyI)-5,6,7,8- tetrahydropyridoI4,3-d]pyrimidin-4- yl]piperidin-4-yl ⁇ butan-l ⁇ one
  • the TASK-3 antagonist assay was designed to determine the inhibition of compounds on the human TASK-3 current.
  • the human TASK-3/pENTR221 clone was ordered from Invitrogen (Cat #IOH45737, accession #NM__016601) and was subcloned into the
  • pcCNA5/FRT/TO vector (Invitrogen #V6520-20).
  • the clone was transfected with Lipofectamine 2000 reagent into TRex-Flp-In-CHO cells. Cells were induced with lOng ml tetracycline overnight before recording and cultured in F-12 (Invitrogen # 1765), 10% Tet approved FBS (BD#631101 Lot#041-05- 016), 100 U/ml Pen-Strep (Invitrogen #15140-122), 500 ug/ml Hygromycin B (Invitrogen #10687-010), and 15 ug ml Blasticidin.
  • the TASK-3 Antagonist Assay was developed using the IonWorks®QuattroTM system from Molecular Devices (Sunnyvale, CA). In this electrophysiology platform cells are sealed on a Population Patch PlateTM (PPC) technology. Electical access is obtained using the Nystatin (Sigma, #N6261). Currents are recorded using a 200ms depolarization to +50 mV followed by a 200 ms ramp from -1 10 - +70 mV for both the pre- and post-compound recordings.
  • the compounds of fonnula I have an IC50 activity of 100 ⁇ or less for the TASK receptor. Many of the compounds of formula I have an IC50 of less than 200 nM. For example, the compounds below have IC 50 ⁇ 3000nM in the "TASK-3 antagonist assay", hi particular, the compounds of Examples 2, 5, 7, 8, 10, 12, and 14 exhibited the followin IC50 nM values;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders which have TASK-1 and/or TASK-3-related damage as a secondary cause.

Description

TITLE OF THE INVENTION
TASK CHANNEL ANTAGONISTS FIELD OF THE INVENTION
The invention relates generally to compounds which act as modulators, e.g., antagonists of TASK channels, particularly, TASK-1 and/or TASK-3, compositions and therapeutic uses thereof. BACKGROUND OF THE INVENTION
Potassium channels are membrane proteins that play an important role in many physiological processes. There are three major families of potassium channel proteins each with structural and functional distinctions characterized by the number of transmembrane domams (2, 4 or 6). The first and second families of potassium channels are the voltage-dependent potassium channels (Kv) and the inwardly rectifying potassium channel (¾). The members of the third family are known as the KCNK, or ¾p (Coetzee W. J. et al; New York Acad Sci, 1999 (868),
233-285) proteins to which the TASK (TWIK-related acid-sensitive potassium) belongs. The TASK channels are generally referred to as TASK-1 (which is also known as (aka) KCNK3 or K2P3J), TASK-2 (aka KCNK5 or K2P5.1), TASK-3 (aka KCNK9 or K2P9.1), TASK-4 (aka KCNK17 or K2P17.1 or TALK-2) and TASK-5 (aka KCNK 15 or K2P15.1). TASK-1 and TASK- 3 channels have the greatest homology within this family with a greater than 0% amino acid identity. For background discussion see Goldstein, S.A.N., et al, Nat. Rev. Neurosci. 2, 175-184 (2001); Lesage, F., et al, Am. J. Physiol. Renal Physiol 279, F793-F801 (2000); Lesage, F., et al, Neuropharmacology 44, 1-7 (2003); and Talley, E.M., Neuroscientist 9, 46-56 (2003).
The TASK channels are sensitive to extracellular pH within physiological range displaying inhibition at acidic pH and activated at alkaline pH (Duprat F., et al., EMBO J. 1997 (16), 5464-5471). TASK-1 is expressed in the brain, spinal ganglia, peripheral tissues such as pancreas, placenta, uterus, lung, heart, kidney, small intestine and stomach, and have been detected in motor neurons of the locus coeruleus and hypoglossal nerve (a motor cranial nerve which is integrally involved in the maintenance of the upper respiratory pathways). TASK-3 channels are primarily expressed in the cerebellum (Medhurst, A.D., et al., Mol Brain Res. 2001 (86), 101-114).
TASK-1 channels have been shown to be involved in respiratory regulation in respiratory neurons of the brainstem, in carotid bodies and motor neurons of the hypoglossal nerve, and also in neuroepithelial cells of the lung. The lowering of the pH and resultant blockage of the pH-dependent TASK-1 channels that occur from inadequate respiration (e.g., hypoxia, hindered breathing, excessive physical stress) leads to depolarization of the cells, which leads to the activation of the neurons involved in the respiratory regulation [Buckler K.J., et al., J. Physiol. 2000 (525), 135-142; Bayliss, D.A., et al., Respiration Physiology 2001 (129), 159-174). Blocking TASK channels, by increasing the activity of chemosensitive neurons in conjuction with activation of the motor neurons of the hypoglossal nerve, can stimulate respiration, stabilize the upper respiratory pathways and protect the pathways from collapse and occlusion.
Stabilization of the upper respiratory pathways can also help eliminate or inhibit snoring. Thus, blocking TASK-1 channels can be beneficial in the treatment of respiratory disorders such as sleep apnea. TASK-1 channesl have also been found in smooth muscle cells of mesenterial and pulmonary arteries, and are suggested to be involved in acidosis-induced pulmonary
vasoconstriction (Gurney A.M., et al., Circ. Res. 2003 (93), 957-964).
It has been shown that TASK-1 channels are responsible for programmed cell death (apoptosis) in granulose cells, and that the ceil death can be preventing by blocking the TASK-3 (Patel A. J., Pflugers Arch, 2004 (448), 261-273). Thus, developing inhibitors of TASK channels, particularly specific inhibitors of TASK-1 and/or TASK-3 channels, could lead to therapeutic treatment of neurodegenerative disorders.
The TASK-3 gene has been found in several human carcinoma tissues (e.g., breast cancer, colon cancer, lung cancer), which leads to the belief that TASK-3 inhibitors may useful as an anticancer drug. See Mu D., et al., Cancer Cell 2003 (3), 297-302; and Pei, L., et al., Proc. Natl. Acad. Sci. USA 2003 (100), 7803-7807. In addition to being an anticancer agent (e.g., breast cancer, lung cancer, colon cancer, prostate cancer), TASK-3 antagonists may also be useful for the treatment of respiratory disorders (e.g., Cheyne-Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia) , sleep disorders, excessive daytime sleepiness, sleep apneas, snoring, neurodegenerative disorders, cognitive impairment (e.g., dementia, Alzheimer's disease) or major depressive disorder, Parkinson's disease, Huntington's disease.
SUMMARY OF THE INVENTION
One aspect of the present invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders which have TASK-1 and/or TASK-3 -related damage as a secondary cause.
Another aspect of this invention is use of the TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prevention of cancer disorders (e.g., breast cancer, lung cancer, colon cancer, prostate cancer), respiratory disorders (e.g., Cheyne-Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia) , sleep disorders, excessive daytime sleepiness, sleep apneas, snoring, neurodegenerative disorders, cognitive impairment (e.g., dementia, Alzheimer's disease) or major depressive disorder, atypical depression, Parkinson's disease, and Huntington's disease.
More particularly, the present invention relates to TAS -1 and/or TASK-3 antagonist of structural formula I or la:
Figure imgf000004_0001
I la
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein:
Rl represents Q-6 alkylC(0)OCi -6alkyl, (CH2)nC6-10aryl, (CH2)nC5-10heterocycle, (CH2)nC3- lOcycloalkyl N(CH3)(CH2)nC(O)NHC6-10aryl, and N(CH3)(CH2)nC5-10heterocycle; said cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of Ra;
R represents H, Q-6 a kyl, C(O)(CH2)nC6-10aryl, C(O)O(CH2)nC6-10ary C(0)(CH2)nC5- lOheterocycle, (CH2)nC6-10aryl, SO2C6-IO ary SO2C5-IO heterocycle, C(O)NHC6-10ary
C(0)C2-4aikynyl, CNC6-10aryl, (CH2)nC5-10heterocycle,or C(O)CH(CH3)N(CH3)CH2C6-10 aryl, said alkynyl, aryl, alkyl, and heterocycle optionally substituted with 1 to 3 groups of Ra;
Ra represents (CH2)nOH, (CH2)nCN, C(OH)CN, Cl-6 alkyl, CH(OH)(CH2)nC6-10 aryl,
CH(OH)(CH2)nC3-10 cycloalkyl, OCl-6 alkyl, 0(CH2)nC2-6 alkenyl, C(0)OCl-6 aikyl, C(0)Cl_6 alkyl, (CH2)nC(O)(CH2)nC3-10 cycloalkyl, (CH2)nC(O)(CH2)nC5-10 aryl (CH2)nC(0)(CH2)nC5- 10 heterocyclyl, (CH2)nC(O)O(CH2)nC3-10 cycloalkyl, (CH2)nC(O)O(CH2)nC5-10 aryl,
(CH2)nC(O)O(CH2)nC5-10 heterocyclyl, halo, (CH2)nC6-l()aryl, O(CH2)nC6-10aryl, (CH2)nC5- lOheterocycle, -N(CH3)CH2C(O)NHC6-10aryl NH(CH2)nC6-10aryl5 -N(CH3)CH2C6-10aryl, - NH(Cl-6alkyl), (CH2)nS02Cl.6alkyl, (CH2)nSO2C6-10aryl, -0-, C3-IO cycloalkyl, -SCl-6 alkyl, CF3, OCF3, CHF2, CH2F, CF30Ci -6alkyl, NH2, C(0)N( Ci _6 alkyl)(CH2)nC5-10heterocyclyl, C(0)N(Ci_6alkyI)2, (CH2)nOC(0)Cl _6alkyl, (CH2)nOC(0)C6-l Qaryl, (CH2)nOC(0)C5_ lOheterocyclyl, (CH2)nOC(O)C3_10cycloalkyl, said alkyl, cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of R3^;
Raa represents C(0)OQ-6 alkyl, 0(CH2)nphenyl, OH, OCH3, SCH3, OCH2CH3, OCH2CF3, CF3, OCF3, CN, Cl-6 alkyl, halo, NHC(0)OCl-6 alkyl, =NOCl-6alkyl, O(CH2)nC6-10ai l;
R3, R3as R4 R4a independently represent hydrogen or C\ -ft alkyl; and n represents 0 to 4.
This invention also relates to compositions and methods for using the compounds disclosed herein. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK- 3, such as cancer disorders (e.g., breast cancer, lung cancer, colon cancer, prostate cancer), respiratory disorders (e.g., Cheyne- Strokes respiration,disrupted central respiratory drive, muscle-related respiratory disorders, acute and chronic lung disorders with hypoxia and hypercapnia) , sleep disorders, excessive daytime sleepiness, sleep apneas, snoring, neurodegenerative disorders, cognitive impairment (e.g., dementia, Alzheimer's disease) or major depressive disorder, Parkinson's disease, and Huntington's disease.
An embodiment of this invention is realized when n in R and Rl is 0-2, preferably
0-1 and more preferably 0.
An embodiment of the present invention is represented by structural formula I:
Figure imgf000005_0001
I
wherein Rl, R, R3, R3 s ? a d 4 are as previously described. Another embodiment of the present invention is represented by structure formula la:
Figure imgf000006_0001
wherein R.1, and R are as previously described.
Another embodiment of the present invention is realized when R1 is
Figure imgf000006_0002
wherein:
y represents H, Ci-^alky C(0)Ci-6alkyl, C(0)C3-i()cycloalkyl, C(O)(CH2)nC6-10aryi=
C(O)(CH2)nC5-10heterocycle, C(0)OCi-6alkyl, (CH2)nC6-10aryl> (CH2)nC5-10heterocycle, said alkyl, aryl, cycloalkyl, and heterocycle optionally substituted with 1 to 3 groups of Ra> RY 1 is the same as Ra; or when two yl are present they may combined to form a C3-10 cyclic group optionally having 1-2 heteroatoms selected from N, O, and S, said cyclic group optionally substituted with 1 to 3 groups of Ra; and Ry2 is H, halo, or OH and all other variables are as described herein.
Another embodiment of the present invention is realized when n in Ryl is 0-1, preferably
0.
Still another embodiment of the present invention is realized when 1 is
Figure imgf000006_0003
and all other variables are as originally described. A subembodiment of this invention is realized when R l is Cl-galls l, C(0)OCi _6alkyl, C(0)Cl_6aIkyl, C3-6c cIoalk l, C(0)C3- gcycloalkyl, C5. 0 heterocycle, said alkyl, heterocyclyl, and cycloalkyi optionally substituted with 1 to
3 groups of R . Another subembodiment of this invention is realized when only 1 Ry is present.
Another embodiment of the present invention is realized when R* is
Figure imgf000007_0001
and all other variables are as originally described. A subembodiment of this invention is realized when R l is Ci _ ealkyl, C(0)OCi -6alkyl, C(0)Oi _6alkyl, C3-6cycloalkyl , C(0)C3-6cycloalkyl, C5-10 heterocycle, said alkyl, cycloalkyi, heterocycle optionally substituted with 1 to 3 groups of Ra. Another
subembodiment of this invention is realized when Ryl is C{0)OCH2CH3, C(0)CH2CH3, C(0)CH3, C(0)(CH2)2CH3, C(0)cyclopropyl, C(OH)(CH3)2, cyclopropylOH, and optionally substituted oxadiazolyl, preferably C(0)OC]¾CH3,or C(0)CH2CH3.
Yet another embodiment of the present invention is realized when 1 is
Figure imgf000007_0002
and all other variables are as originally described. A subembodiment of this invention is realized when R is C(0)C1 -6alkyl, C(O)(CH2)nC6-10aryl, C(O)(CH2)nC5-10heterocycle,
(CH2)nC6-10ary or (CH2)nC5-10heterocycle= sa>d alkyl, aryl, cycloalkyi, and heterocycle optionally substituted with 1 to 3 groups of Ra, and Ryl is Ci -galkyl, CF3, CH2F, said alkyl optionally substitute with 1 to 3 groups of Ra.
Still another embodiment of the present invention is realized when Rl is
Figure imgf000007_0003
and all other variables are as originally described..
Another embodiment of the present invention is realized when R3, R3a; R4 an<j j¾4a are all hydrogen and all other variables are as originally described.
Still another embodiment of this invention is realized when R is C(O)(CH2)nC6~10aryl> C(O)(CH2)nC5-10he erocycle, SO2C6-IO aryl, or SO2C5-10 heterocycle, said aryl and heterocycle optionally substituted with 1 to 3 groups of Ra. A subembodiment of this invention is realized when R is C(O)(CH2)nC6-10aryl substituted with 1 to 3 groups of Ra. Still another embodiment of this invention is realized when R is C(0)phenyl and the Ra substitution is an optionally substituted phenyl group, substituted with 1 to 3 groups of R^. Yet another subembodiment of this invention is realized when R SO2C6-10aryl substituted with 1 to 3 groups of Ra.
Another embodiment of the present invention is realized when R is represented by formula Π:
Figure imgf000008_0001
Π wherein Rw and Rwa are independently selected from the group consisting of H, OC 1 -galkyl, 0(CH2)nC6-l Qsryl, SCl-6alkyl, CF3, OCF3, CN, Cl-6 alkyl, and halo. A subeanbodiment of this invention is realized when Rw and Rwa are both hydrogen.
Another embodiment of the present invention is realized when R is pheny or pyridyl optionally substituted by 1 to 3 groups of Ra. A subembodiment of this invention is realized when R is optionally substituted biphenyl.
Another embodiment of the present invention is represented by structural formula ΓΠ:
Figure imgf000008_0002
m
wherein 3, R3a, Ryl RW an(j Rwa is as previously described. A subembodiment of formula III is realized when Ryl is Q-6aIkyl, C(0)OCl_6alkyl, C(0)Cl -6alkyl, C3-6cycloalkyl , C(0)C3- gcycloalkyl, said alkyl and cycloalkyl optionally substituted with 1 to 3 groups of Ra. Another subembodiment of formula ΠΙ is realized when Ryl is C(0)OCH2CH3, C(0)CH2CH3,
C(0)(CH2)2CH3, C(0)cyclopropyl, C(OH)(CH3)2, cyclopropy!OH. Still another subembodiment of formula III is realized when Rw and Rwa are both hydrogen.
Yet another embodiment of this invention is represented by strucutural IV:
Figure imgf000009_0001
IV
wherein Ry 1 and Rwa are previously described herein. Non-limitimg examples of the compounds of this invention are found in Tables 1-
4:
Figure imgf000010_0001
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Table 2
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Table 3
Figure imgf000024_0002
Figure imgf000024_0003
Figure imgf000025_0001
Table 4
Figure imgf000025_0002
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
When any variable (e.g. aryl, heterocycle, R*, etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence.
Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
When for example, R¾ is -O- and attached to a carbon it is referred to as a carbonyl group and when it is attached to a nitrogen (e.g., nitrogen atom on a pyridyl group) or sulfur atom it is referred to a N-oxide and sulfoxide group, respectively.
As used herein, "alkyl" encompasses groups having the prefix "alk" such as, for example, alkoxy, alkanoyl, alkenyl, and alkynyl and means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, and heptyl. "Alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. Preferably, alkenyl is C2-C6 alkenyl. Preferred alkynyls are C2-C6 alkynyl.
"Alkenyl," "alkynyl" and other like terms include carbon chains containing at least one unsaturated C-C bond. In the case of alkenyl it has a double bond and in the case of alkynyl a triple bond is expected.
As used herein, "fluoroalkyl" refers to an alkyl substituent as described herein containing at least one flurine substituent.
The term "cycloalkyl" refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
The term "Q-6" includes alkyls containing 6, 5, 4, 3, 2, or 1 carbon atoms The term "alkoxy" as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom. The term "alkoxy" also includes alkyl ether groups, where the term 'alkyl' is defined above, and 'ether' means two alkyl groups with an oxygen atom between them. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as 'dimethyl ether'), and methoxyethane (also referred to as 'ethyl methyl ether').
As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, napthyl, tetrahydronapthyl, indanyl, or biphenyl.
The term heterocycle, heterocyclyl, or heterocyclic, as used herein, represents a stable 4- to 7-membered monocyclic or stable 8- to 11-mernbered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The term heterocycle or heterocyclic includes heteroaryl moieties. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyi, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl,
dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl,
imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl,
tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamoφholinylJ thiamorpholinyl sulfoxide, thiazolyl, thiazolmyl, thienofuryl, thienot ienyl, thienyl and triazolyl.
In certain embodiments, the heterocyclic group is a heteroaryl group. As used herein, the term "heteroaryl" refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms;
having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, between one and about three heteroatoms selected from the group consisting of N, 0, and S.
heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyl.
In certain other embodiments, the heterocyclic group is fused to an aryl or
heteroaryl group. Examples of such fused heterocycles include, without limitation,
tetrahydroquinolinyl and dihydrobenzofuranyl.
The term "heteroaryl", as used herein except where noted, represents a stable 5- to 7- membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyi, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heteroaryl groups include, but are not limited to, benzimidazole, benzisothiazole, benzisoxazole, benzofuran, benzothiazole, benzothiophene, benzotriazole, benzoxazole, carbolme, cinnoline, furan, furazan, imidazole, indazole, indole, indolizine, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and N-oxides thereof.
Examples of heterocycloalkyls include azetidinyl, pyrrolidinyl, piperidinyi, piperazinyl, morpholinyl, tetrahydrofuranyl, imidazolinyl, pyrolidin-2-one, piperidin-2-one, and thiomorpholinyl.
The term "heteroatom" means O, S or N, selected on an independent basis.
A moiety that is substituted is one in which one or more hydrogen atoms have been independently replaced with another chemical substituent. As a non-limiting example, substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl, 3-chIoro-4-fiuoro-phenyl, 2,4-fluoro-3-propylphenyl. As another non-limiting example, substituted n-octyls include 2,4-dimethyl-5-ethyl-octyl and 3- cyclopentyloctyl. Included within this definition are methylenes (-C¾~) substituted with oxygen to form carbonyl (-CO-).
Unless otherwise stated, as employed herein, when a moiety (e.g., cycloalkyl, hydrocarbyl, aryl, alkyl, heteroaryl, heterocyclic, urea, etc.) is described as "optionally
substituted" it is meant that the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents. Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular ~CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino,
alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, , alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups. Preferred substituents, which are themselves not further substituted (unless expressly stated otherwise) are:
(a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, and
(b) Q-C6 alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C1-C8 alkyl, SO2CF3, CF3, S02Me, C1-C8 alkenyl, Cl~C8 alkoxy, C1-C8 alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, C2-C8 acylamino, C1-C8 alkylthio, arylalkylthio, arylthio, Cl-C8alkylsulfinyl, arylalkylsulfnyl, arylsulfnyl, C1-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C0-C6 N-alkylcarbamoyl, C2-C15 N,N
dialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclyl, or aryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above.
"Halogen" refers to fluorine, chlorine, bromine and iodine.
The term "mammal" "mammalian" or "mammals" includes humans, as well as animals, such as dogs, cats, horses, pigs and cattle.
Ail patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety and are deemed representative of the prevailing state of the art.
As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, for example, reference to "a primer" includes two or more such primers, reference to "an amino acid" includes more than one such amino acid, and the like.
The phrases "effective amount" or "therapeutically effective amount" mean a concentration of TASK- 1 and/or TASK-3 receptor complex modulator sufficient to inhibit or enhance the effect of the TASK-1 and/or TASK-3 receptor complex. Compounds described herein may contain one or more double bonds and may thus give rise to cis/trans isomers as well as other conformational isomers. The present invention includes all such possible isomers as well as mixtures of such isomers unless specifically stated otherwise.
The compounds of the present invention may contain one or more asymmetric centers and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
In the compounds of generic Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (lH) and deuterium (2H), Protium is the predominant hydrogen isotope found in nature.
Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically- enriched reagents and/or intermediates.
It will be understood that, as used herein, references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations.
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N, N- dibenzylethylenediamine, diethylamine, 2-dtethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorphoHne, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamiiie, trimethylamine, tripropylamine, and tromethamine.
When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
The pharmaceutical compositions of the present invention comprise compounds of the invention (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier, and optionally one or more additional therapeutic agents or adjuvants. Such additional therapeutic agents can include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists, iv) sodium channel antagonists, v) NMD A receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) N 1 antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID"), ix) selective serotonin reuptake inhibitors ("SSRI") and/or selective serotonin and norepinephrine reuptake inhibitors ("SSNRI"), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xBi) valproate, xiv) neurontin (gabapentin), xv) pregabalin, and xvi) sodium channel blockers. The instant compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
The instant compounds have clinical uses for the treatment of epilepsy and partial and generalized tonic seizures. They are also useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and for treating multiple sclerosis. The present compounds are useful for the treatment of tachy-arrhythmias. Additionally, the instant compounds are useful for the treatment of neuropsychiatric disorders, including mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders, dysthymic disorders and atypical depression, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalised anxiety disorders. Thus, another aspect of this invention is the use of the compounds of formula I in the manufacture of a medicament to treat diseases associated with TASK-1 and/or TASK-3 receptor complex,
hi addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats guinea pigs, or other bovine, ovine, equine, canine, feline, rodent such as mouse, species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).
It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents, such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors
(SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RJMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), a-adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, 5-HTiA agonists or antagonists, especially 5-HTIA partial agonists, neurokinin- 1 receptor antagonists, corticotropin releasing factor (CRF) antagonists, and pharmaceutically acceptable salts thereof.
Further, it i s understood that compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions and disorders, as well as to prevent other conditions and disorders associated with calcium channel activity.
Creams, ointments, jellies, solutions, or suspensions containing the instant compounds can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.
Dosage levels from about 0.01 mg/kg to about 140 mg kg of body weight per day are useful in the treatment of neuropsychiatric disorders, or alternatively about 0.5 mg to about 7 g per patient per day. For example, neuropsychiatric disorders may be effectively treated by the administration of from about 0.01 mg to about 75 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day neuropsychiatric disorders may be effectively treated by the administration of from about 0.01 mg to about 125 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 5.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.5 mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may ary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1 mg to about 1000 nig of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors. Such patient-related factors include the age, body weight, general health, sex, and diet of the patient. Other factors include the time and route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
In practice, the compounds of the invention, or pharmaceutically acceptable salts thereof, can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in- water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds of the invention, or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy.- In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
Thus, the pharmaceutical compositions of this invention may include a
pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt. The compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more therapeutically active compounds.
The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, - magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
As described previously, in preparing the compositions for oral dosage form, any of the usual pharmaceutical media can be employed. For example, in the case of oral liquid preparations such as suspensions, elixirs and solutions, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used; or in the case of oral solid preparations such as powders, capsules and tablets, carriers such as starches, sugars, microcrystallme cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be included. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. In addition to the common dosage forms set out above, controlled release means and/or delivery devices may also be used in administering the instant compounds and compositions.
In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars,
microcrystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used to form oral solid preparations such as powders, capsules and tablets.
Because of their ease of administration, tablets and capsules are advantageous oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques
A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet advantageously contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule advantageously containing from about 0.1 mg to about 500 mg of the active ingredient. Thus, a tablet, cachet, or capsule conveniently contains 0.1 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of the active ingredient taken one or two tablets, cachets, or capsules, once, twice, or three times daily.
Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.
Further, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage, and thus should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, and dusting powder.
Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented of the invention, or
pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid, such as, for example, where the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.
In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, and preservatives (including anti-oxidants). Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
Compositions containing a compound of the invention, or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
Further, as described above, the instant compounds can be utilized in combination with one or more therapeutically active compounds, hi particular, the inventive compounds can be advantageously used in combination with i) opiate agonists or antagonists, ii) other calcium channel antagonists, iii) 5HT receptor agonists or antagonists, including 5-HTJA agonists or antagonists, and 5-HTIA partial agonists, iv) sodium channel antagonists, v) N-metbyl-D- aspartate (NMD A) receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) neurokinin receptor 1 (NK1) antagonists, viii) non-steroidal anti-inflammatory drugs (NSAID), ix) selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), x) tricyclic antidepressant drugs, xi) norepinephrine modulators, xii) lithium, xiii) valproate, xiv) norepinephrine reuptake inhibitors, xv) monoamine oxidase inhibitors (MAOIs), xvi) reversible inhibitors of monoamine oxidase (RIMAs), xvii) alpha- adrenoreceptor antagonists, xviii) atypical anti-depressants, xix) benzodiazepines, xx) corticotropin releasing factor (CRF) antagonists, xxi) neurontin (gabapentin) and xxii) pregabalin.
The abbreviations used herein have the following meanings (abbreviations not shown here have their meanings as commonly used unless specifically stated otherwise): Ac (acetyl), AcOH (acetic acid), Bn (benzyl), Boc (tertiary-butoxycarbonyl), Bop reagent
(benzotriazol- 1 -yloxy)tris(dimethylamino)phosonium hexafluorophosphate, DCM
(dichloromethane or methylene chloride), DIEA (diisopropylethyl amine), DMAP (4- (dimethylamino)pyridine), DMF (Ν,Ν-dimethylformamide), DMSO (dimethyl sulfoxide), DPPF (Ι,Γ-bisdiphenylphosphino ferrocene), EDCI (l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), Et3N (triethylamine), , EA or EtO Ac (ethyl acetate), HCOOH (formic acid), HOBt (1-hydroxybenzotriazole), iPrOH (isopropanol), 2CO3 (potassium carbonate), LAH
(lithium aluminum hydride), MeOH (methanol), Ms (methanesulfonyl; mesyl; or S02Me), MsO (methanesulfonate or mesylate), NaHC03 (sodium bicarbonate), MgS04 (magnesium sulfate),
MS (molecular sieves), MsCl (methanesulfonyl chloride), NaH (sodium hydride), Na2S04 (sodium sulfate), , Pd(OH)2 (palladium hydroxide, 20% on carbon), PE (petroleum ether), Ph (Phenyl), POCI3 (phosphorous oxychloride), r.t. or RT (room temperature), Rac (Racemic), , SOCI2 (thionyl chloride), TFA (trifluoroacetic acid), THF (Tetrahydrofuran), , TLC (thin layer chromatography), , , Me (methyl), Et (ethyl), n-Pr (normal propyl), i-Pr (isopropyl), n-Bu (normal butyl), i-Butyl (isobutyl), s-Bu (secondary butyl), t-Bu (tertiary butyl), c-Pr (cyclopropyl), c-Bu (cyclobutyl), c-Pen (cyclopentyl), c-Hex (cyclohexyl).
The present compounds can be prepared according to the procedures provided in the Examples. The following Examples further describe, but do not limit, the scope of the invention.
Unless specifically stated otherwise, the experimental procedures were performed under the following conditions: All operations were carried out at room or ambient temperature; that is, at a temperature in the range of 18-25 °C. Inert gas protection was used when reagents or intermediates were air and moisture sensitive. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000pascals: 4.5-30 mm Hg) with a bath temperature of up to 60 °C. The course of reactions was followed by thin layer cliromatography (TLC) or by high-pressure liquid chromatography- mass spectrometry (HPLC-MS), and reaction times are given for illustration only. The structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or micro-analytical data. When given, yields are for illustration only. When given,. NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent. Conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. Broad; etc. In addition, "Ar" signifies an aromatic signal. Chemical symbols have their usual meanings; the following abbreviations are used: v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liier(s)), mL (milliliters), g (gram(s)), mg (milHgrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).
The procedures described herein for synthesizing the compounds may include one or more steps of protecting group manipulations and of purification, such as, re-crystallization, distillation, column chromatography, flash chromatography, thin-layer chromatography (TLC), radial chromatography and high-pressure chromatography (HPLC). The products can be characterized using various techniques well known in the chemical arts, including proton and carbon- 13 nuclear magnetic resonance ( H and C NMR), infrared and ultraviolet spectroscopy (IK and UV), X-ray crystallography, elemental analysis and HPLC and mass spectrometry
(HPLC-MS). Methods of protecting group manipulation, purification, structure identification and quantification are well known to one skilled in the art of chemical synthesis.
Appropriate solvents are those which will at least partially dissolve one or all of the reactants and will not adversely interact with either the reactants or the product. Suitable solvents are aromatic hydrocarbons (e.g, toluene, xylenes), halogenated solvents (e.g, methylene chloride, chloroform, carbontetrachloride, chlorobenzenes), ethers (e.g, diethyl ether,
diisopropylether, tert-butyl methyl ether, digiyme, tetrahydrofuran, dioxane, anisole), nitriles (e.g, acetonitrile, propionitrile), ketones (e.g, 2-butanone, dithyl ketone, tert-butyl methyl ketone), alcohols (e.g, methanol, ethanol, n-propanol, iso-propanol, n-butanol, t-butanol), N,N-dimethyl formamide (DMF), dimethylsulfoxide (DMSO) and water. Mixtures of two or more solvents can also be used. Suitable bases are, generally, alkali metal hydroxides, alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, and calcium hydroxide; alkali metal hydrides and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride; alkali metal amides such as lithium amide, sodium amide and potassium amide; alkali metal carbonates and alkaline earth metal carbonates such as lithium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, and cesium hydrogen carbonate; alkali metal alkoxides and alkaline earth metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and magnesium ethoxide; alkali metal alkyls such as methyllithium, n-butyllithium, sec-butyllithium, t-bultyllithium, phenyllithium, alkyl magnaesium halides, organic bases such as trimethylamine, triethylamine, triisopropylamine, Ν,Ν-diisopropylethyl amine, piperidine, N-methyl piperidine, morpholine, N-methyl morpholine, pyridine, collidines, lutidines, and 4-dimethylaminopyridine; and bicyclic amines such as DBU and DABCO.
It is understood that the functional groups present in compounds described in the * examples below can be further manipulated, when appropriate, using the standard functional group transformation techniques available to those skilled in the art, to provide desired compounds described in this invention.
It is also understood that compounds of this invention contain one or more stereocenters that may be prepared as single enantiomers or diastereomers, or as mixtures containing two or more enantiomers or diastereomers in any proportion.
Other variations or modifications, which will be obvious to those skilled in the art, are within the scope and teachings of this invention. This invention is not to be limited except as set forth in the following claims.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. Starting materials are made according to procedures- known in the art or as illustrated herein.
Figure imgf000037_0001
Scheme B
Figure imgf000038_0001
The compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail. The general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
The synthesis of the compounds in this invention can be synthesized using one of the methods described in schemes A or B. Cyclocondensation of an appropriately substituted keto ester 1 using formamidine and a base catalyst such as sodium methoxide can provide bicyclic structure 2 which can subsequently be deprotected using catalytic hydrogenation to afford amine 3. Amine 3 can then be coupled using an appropriately substituted carboxylic acid and an amide coupling agent to give intermediate pyrazinone 4 which can be converted the the corresponding chloropyrimidine 5. The penultimate compounds 5 can then be heated with a cyclic amine in the presence of an acid scavenger to afford the final compounds 6 which could be functional ized further depending on the structure of the target.
Scheme B represents an alternative procedure for the synthesis of the claimed compounds and begins with the bicyclic pyrazinone 2 from scheme A above. Chloropyrimidine formation can be effected by the action of an electrophilic halogenating agent such as phosphorous oxychloride to afford intermediate 3. Nucleophilic aromatic substitution with an appropriately substituted cyclic amine can provide intermediate 4 which can then be deprotected using hydrogenating conditions. The resulting amine can then be functionalized using a variety of acylating or sulfonylating agents to provide the desired targets 6.
INTERMEDIATES AND EXAMPLES
The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
INTERMEDIATE 1 Biphenyl-4-yl(4-chloro-7,8-dihydropyrido[4^-d]pyrimidin-6(5H)-yl) methanone
Figure imgf000039_0001
l-Ben2yl-3-ethoxycarbonyl-4-piperidone hydrochloride (12.89 g, 43.3 mmol) was suspended in a sodium methoxide solution in methanol (25 % wt wt, 50 mL, 216. 2 mmol) and formamidine acetate (5.4 g, 51.9 mmol) was added to the mixture. The reaction mixture was refluxed until all of the starting material was consumed (2 h). The methanol was removed under reduced pressure, and the resulting white solid was dissolved in a 3/1 mixture of chloroform / isopropanol. The mixture was washed with water and brine, dried over Na2SC>4, filtered and evaporated to give the desired product as a white solid (9.4 g). MS (ESEI): 242.1 [M+l]÷
Step B:
Figure imgf000039_0002
To a solution of compound 1 (100 g, 0.415 mol),.Pd(OH)2 (23 g), and TEA (200 g, 2.07 mol) in MeOH (1500 mL) was added HCOOH (50 mL) dropwise at 60*0 over 30 mins and after addition, the mixture was stirred at 60°C for additional 5 hours. The reaction mixture was cooled to room temperature and filtered over Celite. The filtrate was concentrated to yield the title compound 2 (65 g) as a yellow solid which was used directly in the next reaction. MS (ESEI): 152 (M+H)+.
Step C:
Figure imgf000040_0001
To a stirred suspension of compound 2 (50 g, 0.3 mol) and NaHCOj (70 g, 0.8 mol) in THF (250 mL) and H20 (80 mL) was added a solution of 4-biphenylcarbonyl chloride (19 g, 0.33 mol) in THF (50 mL) at 0°C over 15 min and the resulting mixture was allowed to stir at rt for additional 3 hrs. A large amount of white solid formed and the mixture was filtered then washed with cool ethanol to give 75 g of compound 3 after drying. MS (ESEI): 332 [M+l]+
Step D:
Figure imgf000040_0002
A mixture of compound 3 (50 g, 0.15 mol), phosphoryl chloride (100 mL, 1.0 mol) and acetonitrile (500 mL) and DMF (2 mL) was heated to reflux at 70°C for 5 hour. After cooling, the mixture was evaporated to give the remaining black residue, which was taken up in DCM (600 mL) and poured into 200 mL of ice-water. The mixture was carefully neutralized with the addition of solid NaHC03 to pH~9. The organic layer was separated and the aqueous layer was washed with DCM twice. The combined organic phase was washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was then purified on silica gel column (MeOH/DCM (0-5%)) to yield the title compound 4 as a brown solid (31 g). MS (ESEI): 35 .0 [M+lf
INTERMEDIATE II
Ethyl l-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl) piperidine-4-carboxylate
Figure imgf000041_0001
Reflux
A mixture of 6-benzyl-5f6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one 1 from Intermediate I, step A (5.0 g, 0.02 mol), phosphorous oxychloride (3.30 mL, 0.035 mol) and acetonitrile (80 mL) and DMF (catalytic amount) was heated at reflux for 3 hours. Then the solvents were reduced in vacuum and the remaining black residue was taken up in dichloromethane (250 mL) and poured over ice. The mixture was carefully neutralized with the addition of solid sodium bicarbonate to pH~8. The layers were separated and the organic was washed with brine, dried over sodium sulfate and concentrated. The residue was purified by column chromatography to yield compound 2 as a yellow oil (3 g). MS (ESEI): 242.1 [M+lf ¾ NMR (DMSO-d6): 8 8.80 (s, 1Η).7.40-7.24 (m, 5H), 3.76 (s, 2H), 3.57 (s, 2H), 2.92 (t, 2H), 2.80 (t, 2H).
Step B:
Figure imgf000041_0002
3
To the solution of compound 2 (5.4g, 20.8mmol) and ethyl isonipecotate (3.92 g, 24.95 mmol) in 100 mL of ethanol was added DIEA (4.02g, 3 i.2mmol) and the mixture was heated to reflux for 4 hours. TLC (DCM: MeOH=T5: 1) indicated that the reaction completed. The reaction mixture was then concentrated and purified by chromatography over silica gel to give compound 3 as pale brown solid (7.2 g) MS (ESEI): 381.4 [M+l]+
Step C:
Figure imgf000042_0001
3 If
A mixture of 3 (4 g, 10.5 mmol), ammonium formate (6.64 g, 105 mmol), palladium hydroxide (1.0 g) in methanol (50 mL) was heated at reflux for 3h. The mixture was cooled to rt and filtered over Celite. The filtrate was concentrated under reduced pressure to yield the crude compound as a yellow oil (3.6 g) which could be stored and used directly without further purification. MS (ESEI): 291.2 [M+l],
Example 1: Biphenyl-4-yI[4-(3-methoxyazetidin-l-yI)-7,8-dihydropyrido [4,3-d]pyrimidin-6(5H)- yljmethanone
Figure imgf000042_0002
Step A
Figure imgf000042_0003
To a solution of Intermediate I (100 mg, 0.29 mmol) in anhydrous DMSO (6 mL) was added 3- methoxyazetidine (176.72 mg, 1.43 mmol) and K2C03 (197.50 mg, 1.43 mmol), then the mixture was heated to 90 °C for 4 hrs. The reaction mixture was cooled to rt and filtered. The filtrate was evaporated and purified by HPLG to yield the desired compound (50 mg). JH NMR (CDC¾) δ 8.44 ( br , IH) , 7.40 ~ 7.69 ( m, 9H) , 4.81(br, 3H) , 4.36 (br, 4H), 3.80 (s, 2H), 3.35 ( s, 3H ), 2.72 ( br, 2H ) .
Example!: tert-butyl 2-[6-(biphenyI-4-yIcarbonyI)-S,6,7,8-tetrahydropyrido [4>3-d]pyrimidin-4-
Figure imgf000043_0001
To a solution of Intermediate I (300 mg, 0.87 mmol) in anhydrous DM SO (15 mL) was added t-butyl 2, . 7-diazaspiro [3.5] nonane-7-carboxyIate (685 mg, 2.61 mmol) and 2CO3 (360 mg, 2.61 mmol). The mixture was heated to 90°C for 4 hrs. The reaction mixture was filtered and he filtrate was evaporated and purified by HPLC to yield compound (350 mg) lB NMR ( MeOD) 3 8.05 ( br, IH ) , 7.40 ~ 7.69 ( m , J = 8.0 Hz, 2H ) , 7.23 ( d, J = 7.3 Hz, 2H ) , 7.15 ( d , J = 7.8 Hz, 2H ) , 7.02 (t, J =7.6 Hz, H) , 6.95 ( t, J =7.4 Hz, 2H ) , 5.04 ( s, IH ) , 4.02 ~ 4.21 ( m, 2H ) , 3.22 ~ 3.66 ( m, 9H ), 2.50 ( s, 2H ), 1.36 - 1.68 ( m, 4H ) , 1.01 ( s, 9H ).
Example 3: ethyl cis-4-{[6-(biphenyI-4-ylcarbonyi)-5,6,7,8- tetrahydropyrido[4,3-d]pyrimidin-4- yl] amino) cyclohexanecarboxylate
Figure imgf000043_0002
Step A
Figure imgf000044_0001
To a solution of Intermediate I (150 mg, 0.44 mmol) and 4-aminocycloliexane carboxylic acid (123 mg, 0.86 mmol) in 2 mL of DMSO was added K2C03 (178 mg, 1.29 mmol), then the mixture was stirred at 80°C for 4hrs. The cooled reaction mixture was neutralized with 2N HC1 to pH~7 and solid deposited, then filtered. The filtered cake was dried in vacuo to give the crude product (150 mg) which was used to next reaction directly. MS (m/z): 457 (M+H)+ .
Step B:
Figure imgf000044_0002
SOC¾ was added to 2 mL of EtOH dropwise at 0°C then the compound from step A above (150 mg, 0.33 mmol) was added to the solution and stirring was continued overnight at rt. The reaction mixture was concentrated and the residue was purified by HPLC to give pure product (60 mg). 'H MR (MeOD): δ 8.56 (s, 1H), 7.73 (d, J=7.1Hz, 2H), 7.63 (d, 7.1Hz, 2H), 7.55 (d, J=7.3Hz, 2H), 7.44 (t, J=6.9Hz, 2H), 7.34-7.37 (m, IH), 4.50-4.60 (m, 2H), 4.33 (s, IH), 3.78-4.13 (m, 4H), 2.92 (s, 2H), 2.63 (s, 1H), 2.19 (s, 2H), 1.64-1.81 (m, 6H), 1.24 (s, 3H). MS (m/z): 485 (M+H)+ .
Example 4: tert-butyl 6-[6-(biphenyl-4~yIcarbonyl)-5,6,7,8- tetrahydropyrido[4f3-d]pyrimidin-4- yl J-2,6-diazaspiro [3.3] heptane-2-carboxylate
Figure imgf000045_0001
Step A
Figure imgf000045_0002
To a solution of Intermediate 1 (300 mg, 0.86 mmol) and the amine (371 mg. 1.29 mmol) in 4 mL of DMSO was added K2C03 (593 mg, 4.29 mmol), then the mixture was stirred at 80°C for 4 hours. The cooled reaction mixture was purified by HPLC to give the desired product (300 mg). ¾ NMR (MeOD): 5 8.45 (s, 1H), 7.75 (d, J=7.4Hz, 2H), 7.66 (d, J=7.5Hz, 2H), 7.56 (d, J=5.6Hz, 2H), 7.45 (t, J=7.6Hz, 2H), 7.37 (t, J=7.3Hz, 1H), 4.8 (br, 3H), 4.01-4.46 (m, 7H), 3.60~3.75(m, 2H), 2.89 (s, 2H), 1.42 (s, 9H). MS (ra/z): 512 (M+H)+ .
Example 5: Biphenyl-4-yI[4-(4-Kiethoxypiperidin-l-yl)-7,8-dihydropyrido [4,3-d]pyrimidin~6(5H)- yljmethanone
Figure imgf000045_0003
Step A:
Figure imgf000046_0001
To a solution of Intermediate I (100 mg, 0.286 mmol) in dioxane (3 niL) was added 4~methoxy-piperidine (66 mg, 0.572 mmol), K2C03 (79 mg 0.572 mmol) and MgS0 (86 mg, 0.716 mmol). The resulting mixture was heated to 70°C and stirred overnight. After cooling to rt, the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by HPLC to give 63.6 mg of the desired product. MS (ESI) m/e 429 (M+H). ¾ NM (CD3OD) δ 8.46 (s, 1H), 7.66 (d, J= 8.4Hz, 2H), 7.57 (d, J=8.4Hz, 2H), 7.46 (d, J=8.0Hz, 2H), 7.37 (t, J=7.2Hz, 2H), 7.20-7.30 (m, IE), 4.60-4.70 (m, 1H), 3.50-4.15 (m, 1H), 3.20-3.38 (m, 3H), 2.80-3.02 (m, 2H), 1.50-2.10 (m, 7H). Example 6: 4'-({4-[4-(cycIopropylcarbonyl)piperidin-l-yl]-7,8-dihydropyrido [4,3-dJpyrimidin- 6(5H)-yl}carbonyI)-3-fluorobiphenyI~2~carbonitriIe
Figure imgf000046_0002
1 2
To a mixture of compound 1 (25 g, 194 mmol) and (Boc)20 (50.7 g, 232 mmol) in 150 mL CH2C12. was added , Et3N (58.8 g, 582 mmol). The solution was stirred at rt overnight. The solvent was removed under reduced pressure to give the crude compound (42 g).
Step B
Figure imgf000047_0001
2 3
A mixture of compound 2 (40 g, 0. 75 mol), Ο,Ν-Dimethyl hydroxylamine (17 g, 0.175 mol), HOBt (11.8 g, 0.088 mol), EDCI (50 g, 0.263 mol), and Et3N (53 g, 0.525 mol) in 300 mL C¾C12 was stirred at it overnight. The solvent was removed under reduced pressure and the crude product was purified by silica gel chromatography ( PE/EtOAc (3:1)) to give an off-white solid compound 3 (41 g).
Ste C
Figure imgf000047_0002
3 4
To a solution of compound 3 (10 g, 36.8 mmol) in 50 mL dry THF was added c-PrMgBr (80.8 mL, 40.4 mmol, 0,5 M) dropwise at 0 °C. The mixture was allowed to stir at rt for another one hour. The mixture was concentrated under reduced pressure. Added 100 mL of water, extracted with EtOAc. The organic layer was washed with an aqueous solution of NaCI (50 mL), dried over Na2S0 and concentrated under reduced pressure give the crude product compound 4 (5.91 g). Ste D
Figure imgf000047_0003
4 5
Compound 4 (5 g, 19.7 mmol) in 30 ml CH2C12 was added 10 mL of CF3COOH. The mixture was stirring at rt for 2 hours. 10% NaOH.(50 ml) was added to quench the solution. The residue extracted with EtOAc, Organic layer was dried on MgS04- The solvent was removed under reduced pressure to give the crude product compound 5 without further purification (2.33 g). tep E
Figure imgf000048_0001
To a solution of 6-benzyl-4-chloro-5,6,7,8-tetraliydro-pyrido[4,3-d]pyrimidine (3.9 g, 15.0 mmol) in EtOH (50 mL) was added compound 5 (2.3 g, 15.0 mmol) and D3EA (3.87 g, 30 mmol). The mixture was stirred at 80 °C for 3 hours then the mixture was evaporated to dryness. The crude product was purified by silica gel chromatography eluted with PE: EA = (5:1) to give the desired product (4.08 g)
Step F
Figure imgf000048_0002
A mixture of compound 6 (2.04 g, 5.41 mmol), ammonium formate (3.4 g, 54.1 mmol) and Pd(OH)2 ( 0.6 g ) in 20 mL MeOH was heated to reflux for 3 hours, then the mixture was filtered. The solvent was removed under reduced pressure to give desired product (1,35 g).
Ste G
Figure imgf000048_0003
7 8
To a solution of compound 7 (200 mg, 0.7 mmol) in 8 ml CH2C12 was added 4~Bromobenzoic acid (140 mg, 0.7 mmol), Bop (340 mg, 0.77 mmol) and DEEA (361 mg, 2.8 mmol). The mixture was stirred at r.t. for 3 hours and the mixture was evaporated to dryness. The crude product was purified by silica gel chromatography eluted with PE: EA = (5 : 1 ) to give desired product (315 g).
Step H
Figure imgf000049_0001
To a solution of compound 8 (418 mg, 0.89 mmol) in toluene and dioxane (8 mL/2 mL) was added dioxaborolan (220 mg, 0.89 mmol), Cs2COs (580 mg, 1.78 mmol), Pd(dppf)C¾ (33 mg, 0.0445 mmol). The mixture was stirring at 80 °C overnight under N¾. The mixture was evaporated to dryness and the crude product was purified by HPLC to give the desired target (287 mg).
Example 7: cycIopropyI(l-{6-[(4'-fluorobiphenyI-4-yl)carbonyl]-5,6,7,8- tetra- hydropyrido[4,3- d]pyrimidin~4-yl}piperidm-4-yl)methanone
Figure imgf000049_0002
Step A
Figure imgf000050_0001
1
A mixture of compound 7 from step F in Example 5 (100 mg, 0.349 mniol), 4'-fiuorobipheny!-4~ carboxylic acid (75.5 mg, 0.349 mmol), BOP (185 mg, 0.419mmol) and DIPEA (180 mg, 1.396 mmol) in DCM (10 mL) was stirred at T for 3 hours. After the reaction was complete, solvent was removed under reduced pressure; the residue was extracted with DCM, washed with water and brine, dried over MgS(¾. DCM was removed under reduced pressure to give the desired product (140 mg). MS (m/z) : 485 (Μ+ΕΓ) ¾ NMR (MeOD, 400 MHz): δ 8.56 (s, 1H), 7.65-7.72 (m, 4H), 7.53-7.55 (d, J=7.6 Hz, 2H), 7.16-7.21 (t, J=8.4 Hz, J=8.8 Hz ,2H), 4.33-4.46(m, 2H), 3.89-4.03 (m, 2H), 3.46-3.53 (t, J=10.8 Hz, J=18.4 Hz, 2H,), 2.84-3.11 (m, 4H), 1.96-2.13 (m, 4H), 0.80-1.49 (m, 6H).
Example 8: l-{l-J6-(biphenyI-4-yIcarbonyl)-5,6,7,8- tetrahydropyrido[4,3-d]- pyrimidin-4- yl]piperidin-4-yl}propan-l-one
Figure imgf000050_0002
A mixture of compound 1 (4 g, 1.75 mol), Ο,Ν-Dimethyl-hydroxylamine (1.7 g, 1.75 mol), HOBt (1.18 g, 8.8 mmol), EDCI (5 g, 26.3 mmol), and Et3N (5.3 g, 52.5 mmol) in 30 mL Ο¾0Ι2 was stirred at r.t. overnight. Solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography eluted with PE/EtOAc (3:1) to give an off-white solid compound 2 (4.1 g).
Step B
Figure imgf000051_0001
2 3
To a solution of compound 2 (4 g, 14.7 mmol) in dry THF (20 mL) was added EtMgBr (32.3 mL, 1 .2 mmol, 0.5 M) dropwise at 0 °C. The mixture was allowed to stir at r.t. for another one hour. The mixture was concentrated under reduced pressure. 40 mL of water was added and the mixture was extracted with EA. The organic layer was washed with an aqueous solution of NaCl (20 mL), dried over Na2S04 and concentrated under reduced pressure give the crude product compound 3 (2.36 g).
Step C
Figure imgf000051_0002
3 4
Compound 3 (2 g, 7.88 mmol) in 12 ml CH2CI2 was added 4 mL of CF3COOH. The mixture was stirred at r.t. for 2 hours. 10% NaOH (20 ml) was added to quench the solution. The residue extracted with EtOAc and the organic layer was dried over gSQj. The solvent was removed under reduced pressure to give the crude product compound 4 (0.93 g).
Step D
Figure imgf000051_0003
To a solution of Intermediate I (1.1 g, 3.1 mmol) in EtOH (15 mL) was added l-Piperidin-4-yl-propan-l- one (437 mg, 3.1 mmol) and DIEA (1.55 g, 12 mmol). The mixture was stirred at 80 °C for 3 hours then the mixture was evaporated to dryness. The crude product was purified by silica gel chromatography eluted with PE: EA =(10:1) to give desired product (0.95 g). MS (m/e): 454 (M + H)+ NMR (MeOD) δ, 8.55 (s, 1H), 7.65-7.74 (m, 2H), 7.56-7.63 (m, 2H), 7.46-7.54 (m, 2H), 7.42-7.44 (m, 2H), 7.36-7.38 (m, 1H), 4.50-4.80 (m, 2H), 4.23-4.60 (m5 2H),3.64-4.12 (m, 2H), 3.36-3.60 (m, 1H), 2.70-3.12 (m, 3H), 2.23-2.69 (m, 2H), 1.64-2.17 (m, mH), 1.16-1.56 (m, 1H), 0.64-1.15 (m, 3H).
Example 9: l-{l-[6-(biplienyl-4~ylcarbonyI)-5,6,7,8- tetrahydropyridoI4,3-d]pyrimidin-4- yl]piperidin-4-yl}butan-l~one
Step A
Figure imgf000052_0001
To a solution of compound 4 (831 mg, 5.3 mmol) in EtOH (50 mL) was added Intermediate I (1.7 g, 4.87 mmol) and DIEA (1.25 g, 9.74 mmol). The resulting mixture was stirred at 80 °C for 3 hours. After cooling to r.t, the reaction mixture was concentrated and the residue was purified by HPLC. MS (ESI) m/e 469 (M+H) ¾ NMR (CD3OD) 5, 8.56 (s, 1H), 7.72-7.75 (m, 2H), 7.67-7.69 (m, 2H), 7.56-7.63 (m, 2H), 7.43-7.49 (m, 2H), 7.36-7.38 (m, 1H), 4.46-4.83 (m, 2H), 3.90-4.07 (m, 2H),3.21-3.72 (m, 2H), 2.95-3.15 (m, 2H), 2.21-2:94 (m, 3H), 1.84-2.19 (m, 2H), 1.63-1.84 (m, 1H),1.13-1.64 (m, 3H),0.58-1.13 (m, 3H).
Example 10: ethy! l-[6-(biphenyl-4-ylcarbonyl)-8i8-dimethyl-5,6,7,8- tetrahydropyrido[4,3- d]pyrimidin-4-yi]piperidine-4-carboxyIate
Figure imgf000053_0001
To a solution of NaH (31 g, 0.795 mol) in THF (200 mL), was added compound 1' (30 g, 0.265 mol) was added dropwise at 0°C under N2. The solution was stirred at this temperature for 30 minutes, then iodomethane (94.11 g, 0.663 mol) was added into the mixture and stirring was continued as the solution warmed slowly to room temperature overnight. Water (300 mL) was added and the aqueous layer was extracted with EA (200 mL) twice. The organic layer was washed with an aqueous solution of NaCl ( 50 mL) and dried over Na2SC> . The organic layer was concentrated under reduced pressure to give compound V (32.1 g) as slight yellow liquid.
Ste B
'2 ^ H?N
NC COOEt Ra-Ni COOEt
2' 3'
The mixture of compound V (0.5 g, 3.54 mmol) and Ra-Ni (0.1 g) in MeOH was stirred at r.t. under H2 atnosphere for 3 hour. The reaction mixture was filtered and concentrated to give the crude product (484 mg) without further purification.
Ste C
Figure imgf000053_0002
To a solution of compound 3' (20 mg, 0.138 mmol) in EtOH (3 mL) was added 3-Bromo-propionic acid ethyl ester (30 g, 0.165 mmol) and triethylamine (28 mg, 0.276 mmol). The mixture was stirring at 80 °C for 3 hours then the mixture was evaporated to dryness under depress. The crude product was purified by silica gel chromatography eluted with PE: EA =(5:1) to give desired product (30 mg).
Figure imgf000054_0001
Compound 4' (7 g, 28.5 mmol) was dissolved with 30 mL of MeOH, then two drops of glacial acetic acid followed by benzaldehyde (3.6 g, 34.1 mmol) were added into the mixture, and the mixture was heated to reflux for 30 min. NaBl¾CN (5.37 g, 85.5 mmol) was added into the mixture at 0°C and the mixture was stirred at r.t for 3 hour. The mixture was concentrated and water was added (30 mL) then the mixture was extracted with EA. The organic layer was washed with an aqueous solution of NaCl (50 mL), dried over NajSOj and concentrated under reduced pressure. The crude product was purified by silica gel chromatography eluted with PE: EA = (4: 1) to give desired product (6.5 mg).
Figure imgf000054_0002
To a solution of t-BuOK (1.6 g, 14.3 mmol) in 20 mL dry THF was added Compound 5' (2.4 g, 7.16 mmol) dropwise at 0 °C. The mixture was allowed to stir at r.t. for another one hour. The mixture was concentrated under reduced pressure. Added 30 mL of water, extracted with EA. The organic layer was washed with an aqueous solution of NaCl (20 mL), dried over Na2S04 and concentrated under reduced pressure give the crude product compound 6' (1.1 g). Step F
Figure imgf000054_0003
A mixture of compound 6' (1.1 g, 3.8 mmol), formamidine acetate (368 mg, 4.57 mmol) and sodium methoxide (1.03 gP 19 mmol) in 5 mL MeOH was heated to reflux for 3 hours, then the mixture was filtrated. Solvent was removed. under reduced pressure, then extracted with EA while PH=7. The org! layer was washed with an. aqueous solution of NaCl (20 mL), dried over Na2S04 and concentrated under reduced pressure give the crude product compound 7' (0.81 g).
Figure imgf000055_0001
A mixture of compound 7' (0.1 g, 0.372 ramol), POCl3 (569 rag, 3.72 mmol) and two drops of DMF in 5 mL CH3CN was heated to reflux for 3 hours. Reduced the solvents and the residue was taken up in CH2CI2 and poured over ice. The mixture was carefully neutralized with the addition of solid sodium bicarbonate to pH = 8. The organic layer was washed with brine, dried over MgS04, and concentrated to give the desired product (72.5 mg).
Step H
Figure imgf000055_0002
9'
To a solution of compound 8' (580 mg, 2.02 mmol) in EtOH (30 mL) was added piperidine-4-carboxylic acid ethyl ester (317 mg, 2.02 mmol) and DIEA (1.04 g, 8.08 mmol). The mixture was stirring at 80 °C for 3 hours then the mixture was evaporated to dryness under depress. The crude product was purified by silica gel chromatography eluted with DCM: MeOH = (20: 1) to give desired product (0.68 g). Step I
Figure imgf000055_0003
10' A mixture of compound 9' (0.4 g, 0.98 mmol), ammonium formate (0.62 g, 9.8 mmol) and Pd(OH)2 ( 0.2 g ) in 10 mL MeOH was heated to reflux for 3 hours, then the mixture was filtered. The solvent was removed under reduced pressure to give desired product (285 mg).
Step J
Figure imgf000056_0001
To a solution of compound 10' (285 mg, 0.448 mmol) in 0 ml C¾C¾ was added biphenyl-4-carboxylic acid (89 mg, 0.448 mmol), Bop (218 mg, 0.493 mmol) and DIEA (231 mg, 1.79 mmol). The mixture was stirring at r.t. for 3 hours then the mixture was evaporated to dryness under depress. The crude product was purified by HPLC to give (175 mg).
Example 11: cis and trans BiphenyI-4-yl{4-[(8aR)-hexahydro-2H-pyrano [3,2-c]pyridin-6(5H)-yI]~ 7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl}methanone
Figure imgf000056_0002
A mixture of compound 1 (4.0 g, 20 mmol), pyrrolidine (2.8 g, 40 mmol) and 4 A MS (5 g) in EtOH 20 mL was refluxed for 16hrs. Acrylic acid methyl ester (1.72 g, 20 mmol) was added to the mixture, and the mixture was refluxed for 4 hrs. After cooled to r.t., the reaction mixture was filtered and concentrated in vacuo. H20 (10 mL) was added to the residue, extracted with EtOAc (20 mL χ 2). The combined organic layers were dried over Na2SO,§, concentrated, and purified by chromatography on silica (CH2C12 : MeOH = 50:1) to give product 2 (5.05 g). Step B
Figure imgf000057_0001
2 3
To a stirred solution of compound 2 (2.85 g, 10 mmol) in EtOH (20 mL) was added NaB)¾ (3.8 g, 100 mmol). The resulting mixture was stirred at r.t, for 4h, quenched with H20 (20 mL) and concentrated in vacuum then extracted with EtOAc (20 mL χ 3). The combined organic layer was dried over Na2S04, concentrated in vacuum to give product 3 (2.03 g) MS (ESI) m/e 260 (M+H).
Step C
Figure imgf000057_0002
To a stirred solution of compound 3 (1.3 g, 5 mmol) and Et3N (0.5 g, 5 mmol) in CH2C12 (10 mL) was added MsCl (570 mg, 5 mmol) and the mixture was stirred at 0 °C for 30 min. The mixture was concentrated in vacuum and 10 mL toluene and K2C<¾ (1.38 g, 10 mmol) were added to the residue. The resulting mixture was stirred at 100 °C for 4 h. After cooled to r.t., ¾0 (10 mL) was added and the mixture was extracted with EA (20 mL x 3). The combined organic layers were dried over Na2S(¾, filtered and concentrated and purified by chromatography on silica (PE : EA = 2:1) to give product 4 (705 mg).
Ste D
Figure imgf000058_0001
Figure imgf000058_0002
A mixture of compound 5 (141 mg, 1 ,0 mmpl), Intermediate I (175 mg, 0.5 mmol) and 2CO3 (414 mg, 3.0 mmol) in anhydrous DMSO (6 mL) was stirred at 120 °C for 5 hrs. After cooling to r.t,, the reaction mixture was filtered. The filtrate was purified by Prep-HPLC to yield trans isomer A (82 mg, 36%) and cis isomer B ( 125 mg, 55%), respectively. trans: MS (ESI) m/e 455 (M+H). ¾ NMR (CDC13) δ 8.50 (s, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 7.2 Hz, 2H), 7.33-7.44 (m, 5H), 4.70 (s, 2H), 4.49 (d, J = 7.6 Hz, 1H), 4.28 (d, J => 8.0 Hz, 1H), 3.96 (d, J = 10.0 Hz, 1H), 3.81 (s, 2H), 3.45 (t, J = 10.8 Hz, 1H), 3.12-3.26 (m, 4H), 2.84 (t, J = 12.0 Hz, 1H), 2.01- 2.05 (m, 1H), 1.46-1.77 (m, 5H). cis: MS (ESI) m/e 455 (M+H). XH NMR (CDC13) δ 8.50 (s, 1H), 7.60 (d, J - 8.0 Hz, 2H), 7.53 (d, J = 7.6 Hz, 2H), 7.32-7.43 (m, 5H), 4.69 (s, 2H), 3.99-4.13 (m, 3H), 3.67-3.79 (m, 4K), 3.47 (t, J = 10.8 Hz, 2H), 3.14 (sf 2H), 1.67-1.94 (m, 6H), 1.16-1.18 (m, 1H).
Example 12: Biphenyl-4-yl{4-(4-(l,3-thiazol-2-yI)piperazin-l-yI]-7,8-dihydro- pyrido [4,3- d]pyrimidin-6(5H)~yJ}methanone
Figure imgf000059_0001
Step A:
Figure imgf000059_0002
1
A mixture of compound 1 (96.7 mg, 0.572 mmol), chloropyrimidine intermediate 2 (100 mg, 0.286 mmol), K2C03 (158 mg, 1.14 mmol) in DMSO (3 mL) was heated to 90°C and stirred overnight. After cooling to r.t., the mixture was filtered, water was added, and extracted with EtOAc (5 mL x 3). The combined organic layers were dried over anhydrous Na2S04 and concentrated in vacuum. The residue was purified by preparative HPLC to afford the desired compound (30 mg). MS (ESI) m/e 483 (M÷H). ¾ NMR (CD3OD) δ 8.65 (s, 1H), 7.73 (d, J= 8.0 Hz, 2H), 7.65-7.50 (m, 4H), 7.42 (d, J= 6.4 Hz, 2H), 7.37-7.20 (m, 2H), 6.92 (s, 1H), 4.14-3.50-(m, 12H), 3.07 (s, 2H).
Example 13: Biphenyl~4-yl{4~[4-(2~hydroxypropaji-2-yl) piperidin-l-yl]-7,8-dihydropyrido[4,3- d] pyrimidin~6(5H)-yl}raethanone
Figure imgf000059_0003
Step A:
Figure imgf000060_0001
2
To a solution of Intermediate II (580 mg, 2 mmol) in 20 mL of anhydrous THF at -78 °C was added a solution of CH3MgBr (1.3 mL, 3.0 M in ether, 4 mmol) in ether dropwise under N2. After the addition, the mixture was stirred at -78 °C for additional 1 h and then slowly warmed to 0°C. TLC showed the starting material was consumed and the mixture was quenched with saturated ¾C1 solution carefully. The aqueous layer was extracted with DCM twice. The combined organic layer was washed with brine, dried over Na2S04 and concentrated to give crude 2 as a brown oil (550 mg), which was used in next step without further purification. MS (m z): 277 (Μ+Η)"
Step B:
Figure imgf000060_0002
2 3
To a stirred solution of compound 2 (550 mg, 2 mmol) and acid biphenylcarboxylic acid (2.4 mmol) in DCM (10 mL) was added HOBT (331 mg, 2.4 mmol) and EDCI (5 mmol) at room temperature and the reaction mixture was allowed to stir overnight. The mixture was diluted with 20 mL of DCM and the combined organic layers were washed with water and brine, dried over Na2S0 , concentrated. The crude residue was purified on silica gel column eiuting with DCM/MeOH (100/1-30/1) to give 410 mg of the desired compound. MS (m/z): 457 ( +H)+ ¾ NMR (CD3OD) 58.561(s, 1H), 7.73 (d, 2H, J=7.2 Hz), 7.69 (d, 2H, J=6.8 Hz), 7.59 (d, 2H, J=7.6 Hz), 7.41-7.49 (m, 3H), 4.42 (br, 2H), 3.93-4.13 (m, 3H), 2.69-3.19 (m} 5H), 1.90-2.03 (m, 3H), 1.49-1.71 (m, 2H), 0.94-1.19 (m, 8H). Example 14: Biphenyl-4-yl{4-[4-(3-ethyl-l,2>4-oxadia«ol-5-yl) piperidin-l-yI]-7,8- dihydropyrido[4,3-if]pyriiiiidin-6(5H)-yl}methanone
Step A
Figure imgf000061_0001
To a solution of intermediate I (50.0 mg, 0.14 mmol) in anhydrous dioxane (3 mL) was added compound 1 (50 mg, 0.28 mmol), K2C03 (58.00 mg, 0.42 mmol) and MgS04 (14 mg, 0.14 mmol). The resulting mixture was heated to 100°C for 6 hrs. The reaction mixture was cooled to r.t., filtered and the filtrate was concentrated in vacuum. The residue was purified by preparative HPLC to yield title compound (9 mg). MS (m/z) : 495 (M+lt) !H MR (CD3OD) 5 8.51 (s, 1H), 7.64-7.66 (d, J=7.2Hz, 2H), 7.46-7.53 (m, 4H), 7.37 (t, J=7.2Hz, 2H), 7.27-7.29 (m, H), 5.41 (s, 1H), 4.20-4.37 (m, 2H), 3.81-3.99 (m, 2H), 3.48-3.58 (m, 2H), 2.90-3.00 (m, 2H), 2.59-2.65 (m, 4H), 1.91-2.20 (m, 4H), 1.12-1.21 (m, 3H).
Example 15: Ethyl l-(6-(4-chlorophenylsulfonyI)-5,6,7,8-tetrahydropyrido- [4,3~d]pyrimidin-4- yl] piperidine-4-carboxylate Step A
Figure imgf000062_0001
! nteremdiato II To a solution of Intermediate Π (50 mg, 0.172 mmol) and Et3N ( 52 mg, 0.516 mmol) in DCM (3 mL) was added 4-chlorophenylsulfonyl chloride (54 mg, 0.258 mmol). The resulting mixture was stirred at room temperature for 3h. The mixture was concentrated at r.t. in vacuum and the residue was purified by preparative HPLC to afford the desired compound (20 mg). MS (m/z) : 465 (M+H+) ¾ NMR (CD3OD) δ 8.47(s, 1H), 7.82 (d, J=7.38 Hz, 2H), 7.61 (d, J-7.15 Hz, 2H), 4.27(s, 2H), 4.23- 4.10(m, 4H), 3.64- 3.53 (m, 4H), 3.41(t, J=12.4 Hz, 2H),-2.93 (s, 2H), 2.82- 2.72 (m, 1H), 2.16- 2.02 (m, 3H), 1.84- 1.71 (m, 2H).
Assay
Determination of compound activity on the TASK-3 channel by
electrophysiology.
The TASK-3 antagonist assay was designed to determine the inhibition of compounds on the human TASK-3 current. To produce the TASK-3 cell line, the human TASK-3/pENTR221 clone was ordered from Invitrogen (Cat #IOH45737, accession #NM__016601) and was subcloned into the
pcCNA5/FRT/TO vector (Invitrogen #V6520-20). The clone was transfected with Lipofectamine 2000 reagent into TRex-Flp-In-CHO cells. Cells were induced with lOng ml tetracycline overnight before recording and cultured in F-12 (Invitrogen # 1765), 10% Tet approved FBS (BD#631101 Lot#041-05- 016), 100 U/ml Pen-Strep (Invitrogen #15140-122), 500 ug/ml Hygromycin B (Invitrogen #10687-010), and 15 ug ml Blasticidin. The TASK-3 Antagonist Assay was developed using the IonWorks®Quattro™ system from Molecular Devices (Sunnyvale, CA). In this electrophysiology platform cells are sealed on a Population Patch Plate™ (PPC) technology. Electical access is obtained using the Nystatin (Sigma, #N6261). Currents are recorded using a 200ms depolarization to +50 mV followed by a 200 ms ramp from -1 10 - +70 mV for both the pre- and post-compound recordings. The compounds of fonnula I have an IC50 activity of 100 μΜ or less for the TASK receptor. Many of the compounds of formula I have an IC50 of less than 200 nM. For example, the compounds below have IC50 < 3000nM in the "TASK-3 antagonist assay", hi particular, the compounds of Examples 2, 5, 7, 8, 10, 12, and 14 exhibited the followin IC50 nM values;
Figure imgf000063_0001
Biplienyl-4-yI{4-[4-(l,3-thiazoJ~
2-yl)piperazin-l-yl]-7,8- dihydro- pyrido [4,3-
12 71 ± 4 d ) py rimidin-6(5H)- yl}methanone
Bip enyl-4-yI{4-[4-(3-ethyl- l,2,4-oxadiazol-5-yl) piperidin-
14 l-yl]-7,8-dihydropyrido[4,3~ 46 ± 5 d] py rimid in-6(5H)- yljmethanone

Claims

WHAT IS CLAIMED:
1. A compound of structural formula I and la:
Figure imgf000065_0001
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein:
Rl represents Q-6 alkylC(0)OCl-6alkyl, (CH2)nC6-10aryl? (CH2)nC5-i Oheterocycle, (CH2)nC3- lOcycloalkyl, N(CH3)(CH2)nC(O)NHC6-10aryl, and N(CH3)(CH2)nC5-10heterocycle; said cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of Ra;
R represents H, Ci-6 alkyl, C(0)(CH2)nC6- 1 Oary 1, C(O)O(CH2)nC6-10aryl! C(0)(CH2)nC5- lOheterocycle, (CH2)nC6-l()atyl, SO2C6-10 aryl, SO2C5..10 heterocycle, C(O)NHC6-10aiyl, C(0)C2-4alkynyl, CNC6-lQaryl, (CH2)nC5-10heterocycle3or C(O)CH(CH3)N(CH3)CH2C6-10 aryl, said alkynyl, aryl, alkyl, and heterocycle optionally substituted with 1 to 3 groups of Ra;
Ra represents (CH2)nOH, (CH2)nCN, C(OH)CN, Ci_6 alkyl, CH(OH)(CH2)nC6-10 aryl,
CH(OH)(CH2)nC3-10 cycloalkyl, OCjU6 alkyl, 0(CH2)nC2~6 alkenyl, C(0)OCl-6 alkyl, C(0)Cl_6 alkyl, (CH2)nC(O)(CH2)nC3-10 cycloalkyl, (CH2)nC(O){CH2)nC5-10 aryl, (CH2)nC(0)(CH2)nC5- 10 heterocyclyl, (CH2)nC(O)O(CH2)nC3-10 cycloalkyl, (CH2)nC(O)O(CH2)nC5-10 aryl,
(CH2)nC(O)O(CH2)nC5-10 heterocyclyl, halo, (CH2)nC6-10aryl, O(CH2)nC6-10aiyl, (CH2)nC5- lOheterocycle, -N(CH3)CH2C(O)NHC6 0aiyl5-NH(CH2)nC6-10aryls -N(CH3)CH2C6-10aryl, - NH(Cl-6alkyl), (CH2)nS02Cl-6alkyl, (CH2)nSO2C6-10 ryl, -0-, C3.10 cycloalkyl, -SCl-6 alky CF3, OCF3, CHF2, C¾F, CF30Cl-6alkyl, NI¾, C(0)N( Cl-6 alkyl)(CH2)nG5-10heterocyclyI, C(0)N(Cl„6alkyl)2, (CH2)nOC(0)Cl-6alkyl, (CH2)nOC(O)C6-10aryl, (CH2)nOC(0)C5- lOheterocyclyl, (CH2)nOC(O)C3-l 0c cloalkyl, said alkyl, cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of Raa;
Raa represents C(0)OCi_6 alkyl, 0(CH2)nphenyl, OH, OCH3, SCH3, OCH2CH3? OCH2CF3, CF3, OCF3, CN, Cl-6 alkyl, halo, NHC(0)OCl_6 alkyl, =NOCl-6alkyl, O(CH2)nC6-10aryl; R3, ]¾3a; R4 R4a independently represent hydrogen or Cl_6 alkyl; and n represents 0 to 4.
2. The compound according to claim 1 represented by structural formula I:
Figure imgf000066_0001
I
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
3. The compound according to claim 1 or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein:
R1 is selected from the rou consistin of:
Figure imgf000066_0002
wherein:
R represents H, Cl-6alk l» C(0)Cl-<5alkyl, C(0)C3_l()cycloalkyl, C(O)(CH2)nC6-10aryl
C(O)(CH2)nC5_10heterocycle, C(0)OCl-6alkyl, (CH2)nC6-10aryl, (CH2)nC5-10heterocycle, said alkyl, aryl, cycloalkyl, and heterocycle optionally substituted with 1 to 3 groups of Raj
R l is the same as Ra; or when two Ryl are present they may combined to fonn a C3_10 cyclic group optionally having 1-2 heteroatoms selected from N, O, and S, said cyclic group optionally substituted with 1 to 3 groups of Ra; and Ry2 is H, halo, or OH.
4. The compound according to claim 3 wherein R1 is
Figure imgf000067_0001
is hydrogen, Ryl is independently selected from the group consisting of hydrogen, Cj-6alkyl, C(0)OCl- 6alkyl, C(0)Cl_6alkyl, C3-6cycloalkyl, C(0)C3-6cycloalkyl, C5-I0heterocycles said alkyl, cycloalkyi, heterocyclyl optionally substituted with 1 to 3 groups of R , and R3, R3a¾ j¾4 ancj R4a are all hydrogen.
5. The compound according to claim 1 wherein R s
Figure imgf000067_0002
, Ry is C(0)Cl-6alkyl, C(O)(CH2)nC6-10aryl, C(0)(CH2)nC5-lOheterocycle, (CH2)nC6-10aryl, or (CH2)nC5-10heterocycle, said alkyl, aryl, cycloalkyi, and heterocycle optionally substituted with 1 to 3 groups of Ra, Ryl is independently selected from the group consisting of hydrogen, Q-galky CF3, C3¾F= said alkyl optionally substitute with 1 to 3 groups of Ra, and R , R3a; R4 arid R a are all hydrogen.
6. The comp in R is represented by fonnula II:
Figure imgf000067_0003
Π or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein: and RW and Rwa are independently selected from the group consisting of H, OC 1 -galkyl,
O(CH2)nC6-10aryl, SCi-6alkyl, CF3, OCF3, CN, Cl-6 alkyl, and halo.
7. The compound according to claim 1 represented by structural formula ΙΠ:
Figure imgf000068_0001
m
or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof wherein: R3, R3a, Ryl [s as previously described and Rw and Rwa are independently selected from the group consisting of H, OCl-6alkyl, O(CH2)NC6-10aryl, SCi-6alkyl, CF3, OCF3, CN, Ci-6 alkyl, and halo.
8. The compound according to claim 7 wherein Ryl is Cl_6alkyl, C(0)OCl_ 6alkyl5 C(0)Cl_6alkyl, C3_6cycloalkyl , C(0)C3-6cycIoalkyl, C5.10 heterocycle, said alkyl, cycloalkyi and heterocycle optionally substituted with 1 to 3 groups of Ra, and Rw and Rw are both hydrogen.
9. A compound according to claim 1 repsented by Tables 1 through 4 or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
10. A compound which is :
tert-Butyl 2-[6-(biphenyl-4-ylcarbonyl)-5J6,7,8-tetrahydropyrido [4}3-d]pyrimidin-4-y]]-2,7- diazasp iro[3.5 ] nonane-7-carboxylate;
Biphenyl-4-yl[4-(4-methoxypiperidin-l-yl)-7,8-dihydropyrido [4,3-d]pyrimidin-6(5H)~yl]methanone; Cyclopropyl(l-{6-[(4'-fluorobiphenyl-4-yl)carbonyl]-5,6,7,8- tetra- hydropyrido[4,3-d]pyrimidin-4- yl}piperidin-4-yI)methanone;
1~{ 1 -[6-(Biphenyl-4-ylcarbonyl)-5 ,6,7,8- tetrahydropyrido[4,3-d]- pyrimidin-4-yl]piperidin-4-yl}propan- 1-one;
Ethyl l-[6-(biphenyl-4-yicarbonyl)-8,8-diraethyl-5,6,7,8- tetraliydropyridot4,3-d]pyriraidin-4- yl]piperidine-4-carboxylate;
Biphenyl-4-yl{4-[4-(l,3-tliiazoi-2-yl)piperazin-l-yl]-7,8-dihydro- pyrido [4,3-d]pyrimidin-6(5H)- yl}methanone;
Biphenyl-4-yl{4-[4-(3-ethyH,2,4-oxadiazol-5-yl) piperidin-l-yl]-7,8-dihydropyrido[4,3-i/]pyrimidin- 6(5H)-y 1 } methanone, or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof.
11. A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to Claim 1.
12. The composition according to claim 11 further comprising one or more therapeutically active compounds selected from the group consisting of opiate agonists or antagonists, calcium channel antagonists, 5HT, 5-HTi A complete or partial receptor agonists or antagonists , sodium channel antagonists, N-methyl-D-aspartate (NMD A) receptor agonists or antagonists, COX-2 selective inhibitors, neurokinin receptor 1 (NKl) antagonists, non-steroidal anti-inflammatory drags (NSAID), selective serotonin reuptake inhibitors (SSRI) and/or selective serotonin and norepinephrine reuptake inhibitors (SSNRI), tricyclic antidepressant drugs, norepinephrine modulators, lithium, valproate, norepinephrine reuptake inhibitors, monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs)a alpha- adrenoreceptor antagonists, atypical anti-depressants, benzodiazepines, corticotropin releasing factor (CRF) antagonists, neurontin (gabapentin) and pregabalin.
13. A method for treating and preventing disorders which are caused by activation or by activated TASK-1 and/or TASK-3 comprising administering to a patient a therapeutically effective amount of a compound of formula I in claim 1 or pharmaceutically acceptable salts, individual enantiomers or diastereomers thereof.
14. A method for treating and preventing disorders which have TASK-1 and/or TASK-3-related damage as a secondary cause comprising administering to a patient a therapeutically effective amount of a compound of formula I in claim 1 or pharmaceutically acceptable salts, individual enantiomers or diastereomers thereof.
15. The method according to claim 13 wherein the disorder is selected from the group consisting of epilepsy, respiratory disorders, neuropsychiatric disorders, mood disorders, depressive disorders, atypical depression, bipolar disorders, panic disorders and sleep disorders.
PCT/US2011/025596 2010-02-25 2011-02-21 Task channel antagonists WO2011106276A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2010/070751 WO2011103715A1 (en) 2010-02-25 2010-02-25 Task channel antagonists
CNPCT/CN2010/070751 2010-02-25
US31994010P 2010-04-01 2010-04-01
US61/319,940 2010-04-01

Publications (1)

Publication Number Publication Date
WO2011106276A1 true WO2011106276A1 (en) 2011-09-01

Family

ID=44507164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/025596 WO2011106276A1 (en) 2010-02-25 2011-02-21 Task channel antagonists

Country Status (1)

Country Link
WO (1) WO2011106276A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137684A1 (en) * 2010-06-01 2013-05-30 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN105503890A (en) * 2014-09-23 2016-04-20 天津药明康德新药开发有限公司 5-tert-butyloxycarbonyl octahydrofuro[3,2-c]pyridine-7-carboxylic acid synthesis method
CN105601639A (en) * 2014-11-19 2016-05-25 上海合全药物研发有限公司 6-tert-butyloxycarbonyl octahydro-2H-pyran[3,2-c]pyridine-8-carboxylic acid synthesis method
US10392376B2 (en) 2017-07-13 2019-08-27 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
CN113194924A (en) * 2018-11-27 2021-07-30 拜耳公司 Method for preparing pharmaceutical dosage forms comprising inhibitors of the TASK-1 and TASK-3 channels and their use in the treatment of respiratory disorders
JP2021527041A (en) * 2018-06-05 2021-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A novel tetrahydro-1H-pyrazino [2,1-a] isoindrill quinoline compound for the treatment of autoimmune diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137684A1 (en) * 2010-06-01 2013-05-30 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
US9199976B2 (en) * 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
EP3181564A1 (en) 2012-11-20 2017-06-21 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN105503890A (en) * 2014-09-23 2016-04-20 天津药明康德新药开发有限公司 5-tert-butyloxycarbonyl octahydrofuro[3,2-c]pyridine-7-carboxylic acid synthesis method
CN105601639A (en) * 2014-11-19 2016-05-25 上海合全药物研发有限公司 6-tert-butyloxycarbonyl octahydro-2H-pyran[3,2-c]pyridine-8-carboxylic acid synthesis method
US10745420B2 (en) 2017-05-26 2020-08-18 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
US10392376B2 (en) 2017-07-13 2019-08-27 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10800769B2 (en) 2017-07-13 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US11434233B2 (en) 2017-07-13 2022-09-06 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
JP2021527041A (en) * 2018-06-05 2021-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A novel tetrahydro-1H-pyrazino [2,1-a] isoindrill quinoline compound for the treatment of autoimmune diseases
JP7374130B2 (en) 2018-06-05 2023-11-06 エフ． ホフマン－ラ ロシュ アーゲー Novel tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune diseases
CN113194924A (en) * 2018-11-27 2021-07-30 拜耳公司 Method for preparing pharmaceutical dosage forms comprising inhibitors of the TASK-1 and TASK-3 channels and their use in the treatment of respiratory disorders

Similar Documents

Publication Publication Date Title
WO2011103715A1 (en) Task channel antagonists
US11535614B2 (en) Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2011106276A1 (en) Task channel antagonists
AU2019210624B2 (en) Cyclopropylamines as lsd1 inhibitors
US9969711B2 (en) NK1 antagonists
US12005054B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
EP2716642A1 (en) Imidazopyridine compound
EP3526207B1 (en) Heterocyclic compounds having activity as modulators of muscarinic m1 and/or m4 receptors in the treatment of cns diseases and pains.
US20190387710A1 (en) Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
JP2010531307A (en) Substituted fused pyrimidines as antagonists of GPR105 activity
EP3544979B1 (en) Oxadiazolones as transient receptor potential channel inhibitors
KR20200033996A (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA3124101A1 (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CN108148060A (en) Substituted heterocyclic compound and its derivative, pharmaceutical composition, Preparation method and use
JP2021500416A (en) A novel alkoxyamino derivative for the treatment of pain and pain-related conditions
JP2022528919A (en) Urea derivative as a MALT1 inhibitor
WO2023187677A1 (en) N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
TW202417435A (en) Targeted protein degradation of parp14 for use in therapy
US20230150981A1 (en) N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonists
WO2023194964A1 (en) Fused pyridazine derivatives as nlrp3 inhibitors
CN117843633A (en) Sulfoximine compounds, pharmaceutical compositions and uses thereof
NZ621092A (en) Compounds and compositions as c-kit kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11747911

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11747911

Country of ref document: EP

Kind code of ref document: A1